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ABSTRACT 
HYBRIDIZED POLYMERIC NANO-ASSEMBLIES: KEY 
INSIGHTS INTO ADDRESSING MDR INFECTIONS 
 
FEBRUARY 2019 
RYAN F. LANDIS 
B.Sc., UNIVERSITY OF PITTSBURGH 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Vincent M. Rotello 
 
 Multidrug-resistant (MDR) bacteria contribute to more than 700,000 annual deaths 
world-wide. Millions more suffer from limb amputations or face high healthcare treatment 
costs where prolonged and costly therapeutic regimens are used to counter MDR infections. 
While there is an international push to develop novel and more powerful antimicrobials to 
address the impending threat, one particularly interesting approach that has re-emerged are 
essential oils, phytochemical extracts derived from plant sources. While their antimicrobial 
activity demonstrates a promising avenue, their stability in aqueous media, limits their 
practical use in or on mammals. Inspired by the versatility of polymer nanotechnology and 
the sustainability of traditional medicine, I employed a hybridization approach to improve 
the stability and subsequently the antimicrobial activity of phytochemical extracts. This 
approach was accomplished through a crosslinked Nano-emulsification templating 
strategy, generating a highly robust and reproducible library of potent oil-in-water Nano-
assemblies. These assemblies, stabilized using synthetic or natural polymers, demonstrated 
long-term shelf life, high stability in serum-containing aqueous environments, and most 
viii 
 
notably, were demonstrated to penetrate highly refractory biofilm infections, eliminating a 
broad-spectrum of pathogenic bacteria where accumulated resistance towards these 
materials were not observed during the course of laboratory experiments. Taken together, 
the technology presented herein, offers key insight into addressing MDR-associated 
infections with hopes that future platforms can be built from to tackle the rising dangers of 
MDR infections. 
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CHAPTER 1 
 
ORIGIN, CHALLENGES, AND STRATEGIES TO 
ADDRESS MULTIDRUG-RESISTANCE 
 
 
 
1.1. Origin and Evolution of Antibiotic-Mediated MDR 
1.1.1 MDR Origin 
The discussion of antibiotic resistance and multidrug-resistant (MDR) bacteria 
have become a “hot topic” issue in recent decades. However, antibiotic resistance 
determinants have been circulating within the microbial genome for millennia and largely 
predates the manufacture and use of antibiotics by humans.1 This observation was observed 
by D’Costa et al.2 who authenticated ancient DNA from 30,000-year-old permafrost 
sediments. The study confirmed a diverse collection of encoded resistant genes towards 
some of the most common antibiotics used world-wide, including β-lactam, tetracycline, 
and glycopeptide classes. Furthermore, these genetics were found to be remarkably similar 
to genes currently expressed by bacteria found in healthcare-associated infections. Given 
that current databases indicate the existence of more than 20,000 potential resistance genes 
(r genes) of nearly 400 different microbial species,3 medical experts are severely concerned 
about the possibility of a return to the preantibiotic era, a time where even simple skin 
laceration infections could result in a quick death.4 
Understanding how these microbial infections develop resistance to certain 
antimicrobials, like antibiotics, is best viewed from first understanding antibiotic 
2 
 
development during the 1900s. Since the first introduction of the sulfonamide antibiotic 
class in 1937,5 along with many other naturally or synthetically derived classes in the 
coming decades, so too was introduced the Modern Medicine paradigm. Without question, 
antibiotics have revolutionized medicine in many respects, saving countless lives ever 
since their first medical implication. Table 1.1 provides a wide range of antibiotic classes 
and subsequently, their mode of action, and mechanisms which pathogenic 
microorganisms develop resistance towards therapeutic intervention.6 Notably, in some 
cases, these antibiotic classes or through finite chemical modifications, can be repurposed 
beyond antibacterial targets, creating a significant number of additional therapeutic 
applications, including antiviral, antitumor, or anticancer agents.7 Two significant 
examples of their nonantibiotic effects include cardiovascular disease and 
immunosuppressive treatments. The dire tradeoff of these benefits is that since their 
introduction, millions of metric tons of antibiotics have been produced with limited 
regulation use world-wide. Furthermore, production improvements over the decades have 
created less expensive agents and have been branded as non-prescription or off-label 
products. Numerous studies have concluded that the sharp rise in antibiotic-resistant 
microbes and their global distributions are a direct result of an unremitting selection 
pressure of antibiotic use by humans. The overuse, underuse, and misuse of antibiotics in 
healthcare, and in fact, largely (~80% of all antibiotics) in agriculture is responsible for the 
rapid development of MDR bacteria.8 It is clear that this process is not natural, but a man-
made event brought upon nature and is arguably the best example of Darwinian notions of 
selection and survival. The review of antimicrobial resistance, published in 2016, has 
concluded that if great lengths are not taken to mitigate the dangers of MDR, by 2050, 10 
3 
 
million lives will be lost each year with incurring healthcare costs reaching beyond $100 
trillion.9 
 
Table 1.1. List of common antibiotic classes, their action mechanism, and common 
bacterium resistant towards their mode of action. 
1.1.2 MDR Evolution 
Given their rapid reproductive cycles and robust capacity to develop resistance 
from external threats, prokaryotes such as bacteria have successfully evaded extinction 
prior to man’s discovery of antibiotics and most notably after their large-scale 
manufacturing and global implementation.10 Bacterial microbes capable of resisting a 
range of antibiotic classes via multiple genetic mutations have coined the name 
“superbugs” and exacerbate the difficulty in treating against these pathogens as the number 
of therapeutic options are limited and increase the duration of hospital care, dramatically 
increasing financial burden in both developing and developed countries.11 Table 1.2 
4 
 
provides a list of these superbugs and their associated infections, along with a list of 
antibiotics they are resistant towards.12 Although it is clear there is a positive correlation 
within a bacterial population between resistance to one drug and resistance to one or more 
other drugs, it is unknown whether each bacterial taxon has inherent resistant mechanisms 
or the extent at which pathways to accumulation of multiple resistances are shared among 
pathogens.13 Figure 1.1 highlights the most common routes of acquired resistance. 
 
Table 1.2. List of common “Superbugs”, common infection sites, and common antibiotics 
they are resistant towards. 
5 
 
 
Figure 1.1. Common routes of acquired resistance. 
1.1.3 Enzyme-Mediated Resistance 
One of the most common forms of resistance involve the degradation or 
modification of antibiotics, in particular, the β-lactamases.14 Endogenously produced by 
pathogens such as K. pneumoniae, these enzymes are highly effective at degrading 
ampicillin, preventing the agent from reaching cells buried within. Furthermore, 
chromosomally encoded AmpC β-lactamase secreted into the matrix of P. aeruginosa are 
additionally capable of lactam antibiotic degradation.15 Interestingly, this has been 
identified as an important and clinically relevant determinant of β-lactam resistance in P. 
aeruginosa. These are only but two examples, where almost 600 class A β-lactamases were 
reported in 2011.16 Most concerning however, is the rapid emergence in clinics of 
carbapenemase found in K. pneumoniae. Carrying over to other pathogenic infections such 
as Enterobacteriaceae, P. aeruginosa, and A. baumannii, this antibiotic degrading enzyme 
continues to spread worldwide.17 
1.1.4 Efflux Pump-Mediated Resistance 
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Another common resistance mechanism found in pathogenic infections are 
acquired efflux pumps on their cellular membranes. Efflux pumps are transmembrane 
proteins designed to simply ‘Pump’ out intracellular antibiotic agents, preventing them 
from reaching their active site and ultimately killing the pathogen.18 Interestingly, efflux 
pumps can aid certain pathogen species like Pseudomonas putida, to grow at a liquid 
interface of water and toluene, extruding the toluene solvent through their TtgABC pump.19 
This resistance mechanism is responsible for protecting pathogens from antibiotics like 
fluoroquinolones, chloramphenicol, florfenicol, streptomycin, sulfonamide classes, and 
tetracycline.20 
1.1.5 Gene Transfer-Mediated Resistance 
Although typically observed to occur at a faster rate (x10,000) in a biofilm setting, 
planktonic pathogens are also capable of transferring plasmids between cells via 
conjugation.21 This plasmid transfer process is by far the most common mechanism of 
Horizontal Gene Transfer (HGT). Most disturbing, however, is that although the most 
common transfer mechanism is plasmid-mediated, it wasn’t until the rise of the ‘antibiotic 
era’ that these r genes began to appear.22 This is supported further by bacterial pathogens 
isolated before the ‘antibiotic era’, while possessing plasmids, rarely had any r gene 
association.23 This discovery further indicates the strongly positive correlation of antibiotic 
use and subsequent resistance. Given that the rate of this gene transfer-mediated resistance 
process occurs more frequently in large bacterial populations, (e.g. biofilms found in 
hospitals, food processing equipment, and even the human gut microbiome) so too rises 
the severity of acquired resistance and therefore decreases the chances of successful 
removal/treatment with any therapeutic intervention.24 
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1.1.6 Target Site Modification-Mediated Resistance 
The most common form of target site modification of bacterial pathogens is 
fluoroquinolone resistance genes of the qnr family.25 These qnr genes encode proteins to 
bind onto bacterial DNA gyrase, effectively preventing fluoroquinolone antibiotics from 
interacting with its target. This mechanism has proven to be highly successful at 
transferring between vastly different species. One example of this transfer has been 
observed in Enterobacteriaceae that derived its qnrA genes from the chromosomes of 
Shewanella algae, a species found predominately in marine and freshwater bodies.26 It has 
been suggested that the reason for this gene migration is in response to the man-made 
induced antibiotic pressure, especially antibiotic usage in livestock settings. Furthermore, 
given the building evidence of qnr-type gene transfer is heavily derived from 
phylogenetically distant bacterial species, (e.g. Shewanella, Stenotrophomonas, Vibrio, 
Enterococcus, Serratia, and Citrobacter) the role of this antibiotic mechanism is likely 
ancestral.27 
 
1.2. Multidrug-Resistance in Biofilm Microcolonies 
While MDR bacteria in their planktonic or ‘free-flowing’ pose a threat to human 
health, their threat is further exacerbated when they colonize onto surfaces.28 Given the 
term, biofilms, these surface-attached microbial cells secrete a highly complex and 
heterogenous extracellular matrix. This matrix severely compromises antimicrobial agent’s 
penetration and subsequently their effectiveness.29 From a physical perspective, this 
extracellular polymeric substance (EPS) is comprised of proteins, nucleic acids, 
phospholipids, and DNA which act like a protective shield, preventing antimicrobial 
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penetration and instead adsorb onto the outer matrix shell.30 Additionally, an external 
extracellular polysaccharide shell creates a hydration shell, preventing key immune 
response cells within a host from recognizing MDR pathogens buried deep within the 
matrix.31 Together, this matrix dramatically reduces the chance of eliminating the threat, 
regardless of the therapeutic used to treat the threat. Furthermore, given the fact that 
biofilms are a highly regulated process that heavily depends on numerous environmental 
and genetic factors that vary from species to species, accurate diagnosis and therefore 
treatment is often erroneous, catalyzing the chance to further increase MDR-associated 
infections. 
1.2.1 Antibiotic Penetration Paradox 
Suggesting poor antimicrobial penetration is the reason for ineffective treatment 
would be a gross simplification. For example, previous studies indicated that the antibiotic 
tetracycline penetrated uropathogenic Escherichia coli biofilms within 10 minutes of 
exposure without any compromise to bacterial cellular viability.32 This has also been seen 
in other antibiotic-biofilm combinations such as ampicillin-Klebsiella pneumoniae and 
rifampin-Staphylococcus. Alternatively, it has been previously demonstrated that 
antibiotics like oxacillin, cefotaxime, and vancomycin (a drug of last resort) was limited in 
their penetration capabilities onto Staphylococcus aureus biofilms, suggesting that in some 
cases, the penetration barrier does contribute to the reduced susceptibility of biofilms to 
certain antibiotic classes.33 Therefore, it has been proposed that slower antibiotic 
penetration may increase the opportunity for adaptive phenotypic responses, potentially 
increasing tolerance. 
1.2.2 Antibiotic-Modifying Enzyme 
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Another advantage the EPS matrix provides is the localization of antibiotic-
modifying enzymes throughout the biofilm. For instance, K. pneumoniae biofilms secrete 
β-lactamase and has been demonstrated to effectively degrade ampicillin, preventing the 
antibiotic from even reaching pathogenic cells.34 Furthermore, certain pathogenic biofilms, 
such as P. aeruginosa grow faster than their counterparts, increasing the total amount of β-
lactamase enzymes within the matrix, further impairing the therapeutic relevance of 
antibiotics.35 
1.2.3 Extracellular DNA 
A particularly interesting resistance mechanism of MDR biofilms is their ability to 
incorporate extracellular DNA (eDNA) throughout the EPS matrix, dramatically enhancing 
both resistance and tolerance of antimicrobials.36 This observation has been best studied in 
P. aeruginosa biofilms. In fact, previous studies have showed that P. aeruginosa biofilms 
can sequester DNA from exogenous sources, resulting in an increased level of resistance 
towards tobramycin by 3-fold and 2-fold for gentamicin.37 One proposed mechanism for 
eDNA’s effect on resistance/tolerance of MDR biofilms is through the alteration of the 
EPS environment. eDNA has been demonstrated to chelate ions such as magnesium (II).38 
Decreasing levels of magnesium leads to the trigger of PhoPQ and PmrAB pathways, two 
processes that contribute to antibiotic resistance. In a similar fashion, eDNA can create 
acidic microdomains throughout the matrix has been observed synergistically with 
magnesium chelation, additionally activating PhoPQ and PmrAB pathways, further 
conferring antimicrobial resistance.39 However, this is one but many observed 
mechanisms, eDNA has been observed to be directly involved in sequestering polyamines 
such as spermidine that localizes on the matrix surface, compromising certain cationic 
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antimicrobial treatment. Finally, eDNA has been observed to contribute directly to 
horizontal gene transfer, a well-known mechanism for transferring resistance genes to 
nearby microbial cells.40 
1.2.4 Biofilm Infections in Hospitals 
Armed with these powerful and creative avenues of defense against antibiotics and 
other antimicrobial agents, numerous MDR biofilm-associated infections have infiltrated 
hospitals on a global scale, imparting high healthcare costs in addition to patient suffering 
and mortality.41 Overall, around 80 percent of hospital-acquired infections are associated 
in one form or another with biofilm formation.42 These infections occur commonly on inert 
surfaces such as indwelling medical devices or inflamed tissues where an injury or incision 
is already present. In particular, P. aeruginosa biofilms cause chronic lung infections in 
cystic fibrosis patients, while pacemaker devices commonly colonize S. aureus biofilms, 
resulting in pacemaker replacement and further patient anguish.43, 44 This challenge is 
further exacerbated by the unavailability of diagnostic techniques capable of distinguishing 
infections as MDR biofilm variants. 
 
1.3. Challenges of Current Methods in Treating MDR 
1.3.1 Antibiotics 
Given the ‘large bag of tricks’ MDR-associated infections have to circumvent 
therapeutic intervention, current antibiotic methods continue to demonstrate marginal 
effect. In some cases, MDR infections are beginning to evolve to become completely 
resistant to any therapeutic admission. Recently, strains of drug-resistant tuberculosis (TB) 
have evolved to be extremely drug-resistant (XDR-TB) to any antibiotic medications such 
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as rifampicin and isoniazid, two first line TB drugs.45 While new derivatives or classes of 
antibiotics could be in theory produced, numerous microbiologists argue against this 
notion. As pointed out by Professor Bob Hancock46 at the University of British Columbia, 
“If we come up with new antibiotics, we’re still going to have those same pressures for 
development of resistance. The drugs that we are producing today are just going to keep us 
in the game; they’re not going to get us ahead of the game. In my opinion, we need to 
change the game.” Professor Hancock is not alone with this notion as experimentalists and 
theoreticians both conclude that rates of antibiotic resistance continue to rise exponentially 
along with a severe reduction in the number of newly discovered antibiotic classes (Figure 
1.2). Furthermore, the antibiotic paradigm, regardless if the correct antibiotic is chosen, 
long-term antibiotic regimens will continue to incur major financial burden for patients and 
hospitals and increase the probability of killing the patient as the concentration of 
antibiotics reach far beyond the safe therapeutic dose.47 
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Figure 1.2. ‘Hockey-Stick Projection’ indicating resistance continues to rise exponentially 
while antibiotic discovery in industry drops to zero in the late 1980s. 
1.3.2 Debridement 
Chronic wounds are typically wounds that cannot heal within a 2 week time-frame 
because of influence factors such as infection and foreign objects.48 Some of the most 
common examples of chronic wounds in the category of ulcers include diabetic foot ulcers, 
pressure ulcers, arterial ulcers, venous ulcers, and fungus-infected wounds.49 Additionally, 
chronic wounds encompass healthcare-associated infections and further complicate 
treatment derived from chronic diseases, vascular insufficiency, diabetes, neurologic 
defects, nutritional deficiency, advanced age, and local factors like pressure, infection, and 
edema. Taken together, these factors severely impair wound healing. A critical tactic to 
enhance wound healing is to perform debridement at the infection site.50 Debridement is a 
general terminology given to the removal of necrotic tissue and foreign objects from a 
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wound to expose viable tissue to both promote and expedite the healing process. Various 
debridement strategies have been implemented including autolytic (self-digestion via hosts 
own enzymes), enzymatic, biodebridement, mechanical, and conservative sharp and 
surgical. In recent decades, new debridement methods have been introduced including 
Versajet technology, ultrasound debridement therapy, hydrosurgery debridement, and 
WoundVac technologies.51 These methods vary in overall effectiveness as comprehensive 
analysis of these techniques is not well establish. While there are an array of reports 
indicating that these debridement methods improve both the rate of healing and overall 
wound healing, accurately determining which method to implement to maximize healing 
is not universally possible. Furthermore, the choice in debridement method largely rests on 
the clinician’s experience coupled with the patience preferences to pain and ethics, the 
clinical context, and overall healthcare costs.52 Detailed contrast studies between all these 
methods are greatly needed as it is unclear which technique offers the greatest chance of 
wound healing capacity. 
 
1.4. Emerging Strategies to Counter MDR 
 
1.4.1 Host-Defense Peptides 
Host-defense peptides (HDPs), also named antimicrobial peptides (AMPs), is an 
evolutionarily ancient component of a hosts innate immune system.53 In fact, more than 
2,700 HDPs have be described thus far in six host Kingdoms (bacteria, archaea, protists, 
fungi, plants, and animals).54 Currently, these HDPs are classified as: 1) α-helical peptides, 
2) peptides containing β-sheet elements, 3) peptides combining both α and β structures, 
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and 4) peptides free of α and β structures and are unusually rich with proline, arginine, 
tryptophan, or histidine resides. Furthermore, HDPs fall into two major mammalian 
antimicrobial peptide classes, defensins and cathelicidins (LL-37 is the only member of 
cathelicidins at the time of this thesis work). In general, HDPs generally contain less than 
50 residues, possess net cationic charge, and contain particularly interesting dynamics 
regarding their hydrophobic and cationic domains, coined “amphiphilic balance”.55 
HDPs offer many advantages over traditional antibiotic agents. HDPs display a 
broad-spectrum activity, killing Gram-negative and Gram-positive pathogens.56 
Additionally, HDPs wide-range mechanisms of action (observed as membrane disruption, 
promoting immune responses via regulating DNA, RNA, and protein synthesis, altering 
gene expression, and stimulating wound healing.) suggest pathogenic microorganisms 
rarely become resistant to them.57 Notably, HDPs have been observed to penetrate biofilms, 
produce synergistic effects with conventional antibiotics, and possess activity towards 
bacteria, viruses, and fungi. Taken together, HDPs offer a promising strategy to address 
MDR-associated infections. However, only a couple examples of HDPs namely 
Gramicidins derived from Bacillus brevis, Polymyxin B isolated from P. polymyxa, 
caspofungin extracted from echinocandin fungi, and iseganan from pig protegrin have 
reached clinical trials.58 The reason for the limited number of current clinical trials comes 
from HDPs poor selectivity, adverse hemolytic (lysis of red blood cells) and host toxicity, 
insufficient stability via protease degradation in vivo, low hydrosolubility and other 
biodistribution challenges, and significant cost of production on a large-scale 
consideration. However, it is of the opinion of this PhD candidate that, excluding his thesis 
work, HDPs is the most promising strategy that has emerged to counter MDR infections. 
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1.4.2 Phage Therapy 
For nearly a century, phage therapy, the use of bacterial viruses (phages), has been 
used to treat bacterial infections. Interestingly, phages are the most abundant biological 
entity world-wide and play a crucial role in regulating bacterial populations, responsible 
for killing 20%-40% of all marine surface bacteria every 24 hours.59 The first successful 
use of phage therapy in a clinical setting was documented in 1919, where four pediatric 
cases of bacterial dysentery were effectively treated. Serious considerations towards phage 
therapy has occurred over the past few decades as the rise of antibiotic resistance became 
apparent. Phages action mechanism is derived from its ability to bind to specific receptors 
on a bacterial cell surface, followed by injecting their genetic material into the host 
pathogen that integrates the material into the bacterial genome.60 An alternative mechanism 
involves the compromise of bacterial replication process and instead produce next-
generation progenies that lyse the host cell. In contrast to lytic phages, lysogenic phages 
undergo a different process. Upon integrating their genetic material within the hosts 
chromosome, these endogenous prophage (a separate plasmid capable of transmitting 
across bacterial generations) can be beneficial to bacterial hosts and impart numerous 
virulence factors that enhance their pathogenicity towards competing microbes or 
mammals.61 Therefore, phage therapy strictly relies on lytic phages combined together as 
a “phage cocktail” which has proven in vitro efficacy against target pathogens. Notably, 
there are a couple examples of lytic phages effectively penetrating biofilms, a remarkable 
capability by any means.62 
While phages have been demonstrated to eliminate key pathogenic bacteria such as 
Clostridium difficile, E. faecium, E. coli, P. aeruginosa, S. aureus, and Enterococcus spp, 
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currently, there are no phage therapy products approved for human use in the EU or United 
States.63 However, there are a couple instances of phage preparations for biocontrol in the 
food industry and have been approved by the FDA under the classification of “generally 
considered as safe.” Regardless of these apparent advantages, phage cocktails can induce 
the possibility of intestinal barrier dysfunction, known as “leaky gut” and significantly 
varies between individuals and the types of phage strains used.64 Although it is unclear of 
the severity of this action, compromised intestinal barrier function has dire downstream 
effects including Crohn’s disease, inflammatory bowel disease, and type 1 diabetes. 
Despite their ease of production, purification, and storage, it is unclear of the universal 
success of these phage cocktails as recent reports indicate potential resistance accumulation 
via horizontal gene transfer.65 It is clear however that additional studies involving the 
interactions between phage, microbiome, and human host are needed before any clinical 
trial considerations are made. 
1.4.3 Antibodies 
Another emerging method to counter MDR infections is to use pathogen specific 
monoclonal antibodies (mAbs).66 Prior to the introduction of antibiotics, mAbs had 
marginal success in the form of serum therapy, performed in the 1940s. However, given 
the inconclusive data on toxicity, high cost, and poor purification methods, antibiotics were 
the chosen cheaper alternative. Following the discovery of murine hybridoma technology 
in the 1970s, biotech and pharmaceutical industries have expanded their antibody 
profiles.67 Prior limitations such as purification, adverse toxicity, and poor scalability were 
eliminated, and the promise of mAb-based therapies have garnered more attention in recent 
decades. Currently, only one mAb treatment, Palivizumab (treatment of respiratory 
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syncytial virus) is licenced in the US, along with several other mAb candidates in advanced 
clinical trials to treat other infectious diseases including HIV, Clostridium difficile, rabies 
prophylaxis, and Staphylococcus aureus. Antibodies offer great advantages over 
antibiotics.68 Their remarkably high specificity prevents adverse off-target effects and 
improved circulation time ensures a more effective treatment. However, antibodies are 
currently best suited for high-risk patients and further work is needed to determine their 
effectiveness as a therapeutic agent when the infection is already present.69 Furthermore, 
antibody therapies heavily rely on rapid diagnostic outputs to enhance the feasibility of 
their use. Currently, diagnostic methods must be improved to ensure the maximum 
therapeutic capacity of antibody therapies. 
 
1.4.4 Quorum Sensing Inhibitors 
Quorum sensing inhibitors (QSIs), while not considered a direct therapeutic, is a 
fundamentally unique approach to reduce the dangers of MDR biofilm infections.70 
Quorum sensing small molecules are used in a variety of bacteria such as Aliivibrio, 
Escherichia, Pseudomonas, and Staphylococcus. QS is a signaling mechanism that enables 
bacteria to adapt their gene expression machinery according to the population density in a 
local environment (e.g. biofilms).71 QS is a critical component to organize light-emitting 
reactions (bioluminescence), to form biofilms, produce antibiotics, express virulence 
factors, and transfer/trade genetic material like HGT. First identified in Vibrio fisheri 
bacterium, these QS molecules are traditionally called autoinducers (AI) and give 
significant advantage to bacterium survival.72 It should be noted, however, that Gram-
negative and Gram-positive use different classes of AI. Gram-negative rely on N-acyl L-
homoserine lactones (AHLs) with conjugated fatty acid chains, while Gram-positive use 
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cyclic thioester peptides. These AIs are either actively transported within the intracellular 
environment (Gram-positive) or passively diffuse through the membrane (Gram-negative), 
although there are some reports of Gram-negative bacterium using active transportation. 
Currently, there are four main methods to block QS: 1) Suppress AI synthesis, 2) target 
AIs through enzymatic degradation reactions, 3) antagonize the QS regulator, and 4) hinder 
the regulator protein from binding to DNA.73 While there are numerous examples of 
successfully using QSI tactics to address MDR infections, significant research gaps still 
remain. First, it is unclear if all molecular components of QS and their respective regulators 
have been discovered.74 Second, only a few clinical trials are underway involving QS 
inhibitors. Third, a better understanding of the complex intricacies of the QS system needs 
to be performed as to avoid adverse effects such as unexpected resistance to QS inhibitors. 
Finally, improved scalability and cost structure of these components must be improved 
before commercial viability is feasible.75 
1.4.5 Essential Oils / Phytochemical Extracts 
Essential oils (EOs) and their separated EO compounds (Phytochemicals) have 
received a renewed interest in the areas of antimicrobials, cosmetics, food, and textiles.76 
These compounds are typically obtained from plant materials including flowers, buds, 
seeds, leaves, twigs, bark, herbs, wood, fruits, and roots and represent a small fraction of 
plant composition (~5% dry vegetation). Table 1.3 provides a list of common 
phytochemicals, their molecular structure, their plant source, and some biological 
activities.77 Nearly every EOs available on the market are obtained by hydro-distillation 
although other classical methods such as organic solvent extraction and cold pressing along 
with innovative methods such as supercritical fluid extraction and solvent-free microwave 
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extraction processes are implement in certain cases.78 The value of EOs has been well 
documented as antibacterial, antifungal, antiviral, pest, and insect repellant agents found 
across biomedical, food, and textile industries. In fact, numerous studies have even 
highlighted EOs value to treat multidrug-resistant bacteria such as Staphylococcus aureus 
and P. aeruginosa.79 Furthermore, EOs offer a viable option against nosocomial infections, 
showing promise as a cleaning liquid for disinfecting medical equipment and surfaces. 
Interestingly, it has been suggested that EOs use on hospital patients offer a feeling of 
psychic comfort thanks to their inherent pleasant odors. Given EOs possess high 
biocompatibility, low-cost, and potent physicochemical properties with respect to their 
environment, EOs have been used in important food preservative applications to fight 
against dangerous food poisoning bacteria such as Listeria monocytogenes, Salmonella 
typhimurium, Clostridium perfringens, Pseudomonas putida, and Staphylococcus aureus.80 
Notably, EOs are gaining traction as health and growth promoters in livestock. The reason 
for this dramatic change is in response to the dramatic rise of MDR pathogens, causing the 
European Union to prohibit synthetic antibiotics in livestock in 2006 and the recent 
Veterinarian Feed Directive implemented by United States Food and Drug Administration 
(FDA).81 The FDA recognizes EOs as safe substances according to Code of Federal 
Regulations, with many compounds approved for use as antibacterial additives. Taken 
together, EOs and phytochemical extracts offer an immense advantage over antibiotics and 
other emerging strategies to combat MDR infections. 
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Table 1.3. List of common phytochemicals and their structure, plant source, and some 
biological activities. 
1.4.6 Limitations 
While there are clear advantages to supplement current antimicrobials with EOs, a 
variety of fundamental limitations prevent their universal adoption.82 The first limitation is 
in their name, Essential Oils. These compounds, typically liquid oils at room temperature 
have almost no solubility in water, causing phase separation and an ineffective delivery 
avenue in aqueous environments. Second, EOs are unstable and in some cases are highly 
volatile, and can be easily degraded by oxidation, volatilization, heating, and light.83 
Finally, depending on the external environment plants are subjected to, the ratio of 
phytochemical extracts across different plant batches can vary marginally and, in some 
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cases, significantly. Strict isolation of EOs into phytochemical extracts can resolve this, 
however in some cases, manufacturing costs often increase, limiting applications that 
require substantial plant oil material. Therefore, it is critical to develop avenues of 
encapsulating these EOs and phytochemical extracts to not only improve their stability and 
solubility but enable their universal application in aqueous-based products, such as those 
found in biomedical and agriculture industries. 
1.4.7 Encapsulation Strategies 
Encapsulation of EOs and phytochemical extracts has been well-documented in 
recent decades and are compartmentalized into microparticles, nanoparticles, and 
liposomes.84 These vehicles have demonstrated dramatic improvement in release profiles, 
enhanced activity, improved thermal stability, and prolonged activity.85 Carefully selected 
materials are chosen to stabilize the oil in a water matrix, otherwise known as oil-in-water 
emulsions. In the context of this thesis, polymeric materials will be discussed, although 
there are examples in literature of using micron and nano-sized particles such as iron oxide, 
and silica-cored materials.86,87,88 Most literature articles discussing EO encapsulation rely 
on nature-derived materials such as chitosan, Alginates, and starches.89 In particular, one 
valuable synthetic polymer stabilizer, poly lactic-co-Glycolic Acid (PLGA) has been used 
in some cases due to its high biocompatibility and biodegradability.90 Although a wide-
range of applicable EO delivery vehicles have been created, fundamental challenges 
regarding their commercial feasibility still remain unaddressed. First, while current 
stabilizers do improve EO stability in aqueous environments, long-term shelf-life 
demonstration remains to be seen across every EO formulation. In particular, carvacrol, an 
immensely potent antimicrobial agent suffers from vehicle aggregation, leading to Ostwald 
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ripening (emulsion size growth) and phase separation between oil and water.91 Second, 
research into crosslinking these emulsions after oil-temptation is scarce, with only a few 
examples of in-situ polymerization found in literature.92 Addressing this second point will 
additionally improve the chances of resolving the first challenge. Third, while there are 
examples of encapsulated EOs eliminating MDR pathogens, these cases are typically 
performed with planktonic pathogens, with almost zero examples of these EO vehicles 
capable of penetrating and eliminating MDR biofilms.93 Once these three challenges are 
resolved, the final consideration will be to reproducibly generate EO vehicles 
demonstrating in vivo or field trial success that can be appropriately scalable for their 
intended application whether its target application is biomedical, agriculture, food, or 
textile industries. 
“It is the opinion of this PhD candidate that if the following considerations can be 
effectively addressed, coupled with their impressive physiologic properties and the chance 
to mitigate drug-resistance without harming hosts or the environment, EO vehicles will 
almost certainly become valuable platforms to build additional formulations to combat 
MDR infections found world-wide.” 
 
1.5. Dissertation Overview 
 
The fundamental goal of this thesis is to address three of the four key challenges 
preventing the commercialization of phytochemical encapsulated vehicles in the areas of 
biomedical and other easily translatable industries found in agriculture. Therefore, chapter 
2 starts with creating a suitable polymeric stabilizer that can be reproducibly crosslinked 
at an oil-water interface, generating nanocomposite-type phytochemical vehicles along 
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with reporting its characterization, activity (biofilm penetration and elimination of 
pathogens within), and viability as a wound-healing agent. Chapters 3 and 4 focus on 
engineering this polymeric stabilizer to include responsive chemical moieties to degrade in 
the present of biologically relevant stimuli including pH, small molecule, and enzymatic 
processes. Furthermore, careful consideration into their characterization, activity, and 
application viability are monitored to ensure cross-platform applicability. Chapter 5 
discusses the use of combining nature-derived stabilizers with a biocompatible crosslinking 
strategy to generate phytochemical emulsion platforms easily scalable for commercial 
industries like biomedical and agriculture. Additionally, their cross-platform 
characteristics and application capabilities is confirmed. Chapter 6 begins to explore 
engineering strategies to develop synthetic polymeric nanoparticles as alternative 
candidates to host-guest peptides. These polymeric particles were found to have impressive 
therapeutic indices that improve upon current peptides and their synthetic analogs. 
Additionally, these polymers were also capable of penetrating and eliminating biofilms and 
show promise as a wound-healing agent. Chapter 7 concludes with a discussion on why 
phytochemical emulsion vehicles and engineered polymeric nanoparticles penetrate and 
easily distribute throughout the entire biofilm’s matrices generated by pathogenic 
bacterium and offers experimental suggestions going forward. 
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CHAPTER 2 
 
CROSSLINKED POLYMER-STABILIZED 
NANOCOMPOSITES FOR THE TREATMENT OF 
BACTERIAL BIOFILMS 
 
 
2.1. Introduction 
Multidrug-resistant (MDR) bacterial infections are a rapidly emerging health 
challenge.1 MDR bacterial infections are responsible for 700,000 deaths each year world-
wide, with more than 10 million predicted deaths per year by 2050.2 A key threat is 
provided by biofilm infections3 of wounds and indwelling systems such as catheters,4 joint 
prosthesis,5 and other medical implants.6 Biofilms secrete extracellular polymeric 
substance7 (EPS), acting as a protective barrier against antibiotics and limiting the efficacy 
of drugs including vancomycin,8 teicoplanin,9 and colistin10 deemed as, “drugs of last 
resort”. Excising infected tissues/implants11 and long-term antibiotic therapy12 are 
currently the best treatments for combatting biofilm-based infections but these invasive 
approaches have obvious limitations, including patient suffering and inconvenience and 
extensive health care costs.13 
Phytochemical14,15 extracts from plants are responsible for their self-defense 
against microbial agents,16 making them promising tools to combat MDR bacteria.17 These 
essential oils are of particular interest as “green” antimicrobial agents18 due to their low 
cost,19 biocompatibility,20,21 and potential anti-biofilm properties.22 Previous studies have 
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demonstrated that many essential oils are cytotoxic towards pathogenic bacteria,23,24 
however poor solubility25 and stability26 in aqueous media has substantially limited their 
therapeutic application. Essential oils can be encapsulated into surfactant27 and 
nanoparticle-stabilized28 colloidal delivery vehicles to enhance their aqueous stability and 
antimicrobial activity against bacteria with applications in food and beverage industries.29 
However, these carriers can be colloidally unstable,30 significantly impairing practical use, 
particularly in complex media such as serum. 
We hypothesized that using a polymer-stabilized essential oil platform would 
enable us to generate nano-sized emulsions to improve the delivery of the payload,31 and 
to increase its stability32 by incorporating crosslinking strategies. Herein, we report an 
essential oil-in-water crosslinked polymer nanocomposite (X-NC) for the treatment of 
bacterial biofilms (Figure 2.1). These nanocomposites exhibit high stability in storage 
(Supporting Figure 2.7) and serum, and rapidly penetrate into biofilms as evidenced by 
confocal experiments. Most importantly, X-NCs efficiently eradicate multiple pathogenic 
biofilms including methicillin-resistant Staphylococcus aureus (MRSA). The therapeutic 
potential of this system demonstrated using a fibroblast-biofilm co-culture wound 
infection model that demonstrated essentially complete elimination of bacteria while 
maintaining high fibroblast cell viability. 
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Figure 2.1. Strategy used to generate antimicrobial composites a) Carvacrol oil with 
dissolved p-MA-alt-OD is emulsified with an aqueous solution containing the PONI-
GAT polymer. The amines on PONI-GAT react with the anhydride units on p-MA-alt-
OD. This crosslinking reaction simultaneously pulls PONI-GAT into the oil phase as the 
polymer becomes more hydrophobic, generating an oil-containing nanocomposite 
structure. b) TEM micrograph of X-NCs. Scalebar is 100 nm. c) Chemical structure of 
PONI-GAT. d) Chemical structure of p-MA-alt-OD. e) DLS histogram indicating the size 
distribution of X-NCs in phosphate buffer saline (150mM). f) Proposed mechanism of 
biofilm disruption. 
 
2.2. Results 
2.2.1 Generation and Characterization of Nanocomposites 
Poly(oxanorborneneimide) polymers (PONIs) were used to stabilize and crosslink 
the essential oil nanocomposites, providing a well-controlled,33 easily modulated,34 and 
scalable platform.35 PONI was designed using three components. First, incorporating 
amines onto PONI would enable fast reactions with crosslinkable electrophiles loaded into 
the oil core as PONI approaches the oil interface. The commercially available poly(maleic 
anhydride-alt-octadecene (p-MA-alt-OD) was chosen as the electrophile to ensure 
effective crosslinking.36 Second, guanidinium moieties were added to enable binding with 
34 
 
bacterial membranes37 along with charge neutralization with the carboxylates released 
from the anhydrides,38 enabling PONIs to partition further into the oil phase for further 
amidation reactions. Finally, tetraethylene glycol monomethyl ether (TEG-ME) groups 
can impart further amphiphilicity, ensuring PONIs are water-soluble yet can partition into 
the oil. Therefore, we synthesized a copolymer PONI bearing guanidine, amine, and TEG-
ME units (PONI-GAT) at a 35-35-30 monomer ratio respectively (Supporting Figure 2.8).  
PONI-GAT, carvacrol oil and p-MA-alt-OD were used to generate antimicrobial 
nanocomposites. Nanocomposites were created by emulsifying carvacrol oil loaded with 
p-MA-alt-OD or carvacrol only (non-crosslinked control) into water adjusted to a pH of 
10 containing PONI-GAT (The pH was adjusted to ensure nucleophilicity of the amines 
on PONI-GAT). Upon emulsification, PONI-GAT partitions to the oil-water interface to 
initially stabilize the carvacrol oil droplets and with p-MA-alt-OD present, crosslinking 
further stabilizes the oil droplets in water. Multiple formulations of PONI-GAT and p-
MA-alt-OD were tried to generate the smallest and most stable formulation. With a final 
PONI-GAT concentration of 6 µM and 10 wt% of p-MA-alt-OD, nanocomposites (10 
wt% X-NCs) of ~250nm were generated, as shown by transmission electron microscopy 
(TEM) and dynamic light scatter (DLS). Furthermore, the surface charge of 
nanocomposites was determined by zeta potential studies (Supporting Figure 2.9) showing 
an overall negative charge resulting from the crosslinking reaction between amines and 
anhydrides, generating carboxylates and imparting negative charge at the oil-water 
interface.  
Further characterization of the generated emulsions was performed with confocal 
microscopy. We hypothesized that reacting PONI-GAT with p-MA-alt-OD would change 
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its inherent hydrophobicity and enhance its partitioning within the oil. To test this 
hypothesis, tetramethylrhodamine-5-isothiocyanate (TRITC, red fluorescence) was 
conjugated to PONI-GAT while 3,3-Dioctadecyloxacarbocyanine (DiO, green 
fluorescence) was loaded within the oil. In addition, the formulation was modulated to 
generate micron-sized emulsions so that confocal experiments could be performed. As 
shown in Figure 2.2a, both green and red fluorescence was co-localized within the oil, 
indicating a composite morphology.  
After characterizing the physical properties of the nanocomposite, chemical 
properties within the composite structure were characterized using FTIR and fluorescamine 
assays. Attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR) 
indicated complete loss of anhydrides and formation of amides/carboxylates after 
nanocomposite fabrication (Supporting Figure 2.10). To further explore the crosslinking, a 
fluorescamine assay39 (Figure 2.2b) was performed to identify the progression of the 
reaction between amines on PONI-GAT and the anhydrides on p-MA-alt-OD.40 PONI-
GAT was used to generate a calibration curve relating to the polymer concentration and 
the respective fluorescence generated from the assay (Supporting Figure 2.11). We 
expected that as the p-MA-alt-OD wt% increases within the oil, more amines will react, 
and the overall fluorescence generated from fluorescamine will decrease. The results show 
that a substantial reduction in amines on PONI-GAT occurs as p-MA-alt-OD wt% 
increases, with almost complete conversion at 10 wt%.  
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Figure 2.2. Physical and chemical characterization of X-NCs. Confocal micrograph of a) 
crosslinked micron-sized composites. PONI-GAT was partially labeled with TRITC (red 
fluorescence) and the oil core is loaded with DiO (green fluorescence). PONI-GAT labeled 
with TRITC can be seen co-distributed with the hydrophobic core indicating a composite 
(as opposed to core-shel) morphology. b) Fluorescamine assay to determine the percentage 
of remaining amines on PONI-GAT after X-NCs formation. 
 
2.2.2 X-NCs Penetration into Biofilms 
Effective treatment of biofilms requires penetration of antimicrobial agents into the 
film.41 We next probed the ability of X-NCs to penetrate into biofilms. X-NCs loaded with 
DiO within the oil were used to track their delivery into biofilms formed by red fluorescent 
protein (RFP) expressing Escherichia coli. As shown in Figure 2.3, the X-NCs diffuse into 
the biofilm matrix and efficiently disperse throughout the biofilm, co-localizing with the 
bacteria. This data supports X-NCs deliver their payload and that the oil core and 
nanocomposite fabrication strategy are operative for effective delivery. 
37 
 
 
 
Figure 2.3. Confocal image stacks of E. coli DH5α biofilm after 3 h treatment with 10 wt% 
X-NCs. DiO was loaded into X-NCs to track them throughout the biofilm. The overlay 
shows X-NCs completely penetrate the biofilm, co-localizing with bacteria that expresses 
red fluorescent protein. Scale bars are 30 µm. 
 
2.2.3 Antimicrobial Activity of X-NCs Against Biofilms 
Next, we investigated the therapeutic efficacy of the X-NCs against multiple Gram 
positive and negative biofilms. Four pathogenic bacterial strains of clinical isolates, 
Pseudomonas aeruginosa (CD-1006), Staphylococcus aureus (CD-489, a methicillin-
resistant strain), Escherichia coli (CD-2), and Enterobacter cloacae (E. cloacae, CD-1412) 
complex were chosen to test our system. As shown in Figure 2.4, X-NCs were able to 
effectively kill bacterial cells in all four biofilms within three hours. The individual 
components used to generate the nanocomposites were used as controls and they showed 
minimal toxicity to biofilms indicating that the combination of all components to generate 
X-NCs is critical for maximum therapeutic efficiency. Notably, X-NCs are able to 
effectively treat both Gram negative (E. coli, P. aeruginosa, and E. cloacae complex) and 
Gram positive (S. aureus) bacteria, demonstrating the broad-spectrum activity of X-NCs. 
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Figure 2.4. Viability of 1 day-old biofilms. (a) E. coli (CD-2), (b) S. aureus (CD-489), (c) 
P. aeruginosa (CD-1006), and (d) E. cloacae complex (CD-1412) biofilms after 3 h 
treatment with 10 wt% X-NCs, carvacrol oil, and PONI-GAT at different emulsion 
concentrations (v/v % of emulsion). The results are an average of triplicates, and the error 
bars indicate the standard deviation. 
 
2.2.4 Eradication of Biofilms in a Co-culture Model 
Treatment of bacterial infections on human tissues and organs is even more 
challenging and relevant for medical applications. Biofilm infections associated with 
wounds and indwelling implants interfere with the host’s ability to regenerate damaged 
tissue.42 In particular, fibroblasts play an important role during wound healing by aiding to 
close the area and rebuild necessary extracellular matrix within the skin.43 We used an in 
vitro co-culture model comprised of mammalian fibroblasts cells with a biofilm grown over 
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them. P. aeruginosa bacteria were seeded with a confluent NIH 3T3 fibroblast cell 
monolayer overnight to generate biofilms prior to X-NCs treatment. The co-cultures were 
treated with X-NCs for three hours, washed, and the viabilities of both bacteria and 
fibroblasts were determined.  As shown in Figure 2.5, X-NCs effectively treated the biofilm 
infection while 3T3 fibroblast viability was largely unaffected.  A four-fold log reduction 
(~99.5%) in biofilm colonies was obtained at 15 v/v% of X-NC emulsion. 
 
 
Figure 2.5. Viability of 3T3 fibroblast cells and P. aeruginosa biofilms in the fibroblast-
biofilm co-culture model after 3 h treatment with 10 wt% X-NCs at different emulsion 
concentrations (v/v % of emulsion). Scatters and lines represent 3T3 fibroblast cell 
viability. Bars represent log10 of colony forming units in biofilms. The results are an 
average of three runs and the error bars indicate the standard deviations. 
 
2.2.5 Serum Stability of X-NCs 
Nanoemulsion stability in serum media is critical for its application both topically 
and systemically.44,45,46,47 Negatively charged serum proteins can bind onto delivery 
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vehicles, forming a corona which can significantly alter their biological identity.48,49 Our 
crosslinked nanocomposite vehicle which bears a negatively charged surface should be 
resistant to serum protein adsorption. X-NCs were incubated with 10% serum media for 
two days and analyzed using DLS. As shown in Figure 2.6a, 10 wt% X-NCs showed 
stability with no evidence of destabilization/aggregation. As a control, non-crosslinked 
analogs using the same formulation minus p-MA-alt-OD showed no stability in serum 
(Supporting Figure 2.12). In addition, DiO was loaded into both crosslinked 
nanocomposites and non-crosslinked analogs and incubated in serum for one hour. 
Destabilization of the non-crosslinked analog would result in leakage and quenched 
fluorescence of the loaded dye.50 Figure 2.6b shows that DiO maintains its fluorescence 
within the X-NCs while its non-crosslinked analog shows no fluorescence, further 
supporting the stability of X-NCs in serum conditions.  
 
Figure 2.6. Stability of X-NCs in 10% fetal bovine serum (FBS). a) DLS histogram of 10 
wt% X-NCs in 10% FBS after two days. Destabilization/aggregation of the X-NCs was not 
observed. b) Fluorescence spectra of loaded DiO in 10 wt% X-NCs and non-crosslinked 
analog. Serum proteins destabilizes the non-crosslinked analog, leaking out DiO, and 
quenching the fluorescence whereas X-NCs maintain fluorescence indicating stability.  
Excitation of DiO = 490nm. 
 
 
2.3. Conclusions 
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In summary, we report the fabrication of a polymer-stabilized oil-in-water 
nanocomposite that demonstrates high therapeutic activity towards pathogenic biofilms. 
These nanocomposites show good stability in serum and can effectively penetrate 
throughout biofilms. Furthermore, specific elimination of a biofilm infection while 
maintaining fibroblast viability in an in vitro co-culture was observed. The polymer-based 
crosslinked essential oil-in-water nanoemulsion strategy we present is a promising 
antimicrobial platform, opening new applications to treat wound biofilms and other 
biofilm-based infections. Given the limited capabilities of current topical therapeutics, we 
envision these nanocomposites as powerful new tools for skin-associated infections.  Going 
further, the efficacy and modularity of this system will enable the use of essential oil-based 
composites as antimicrobial additives for foods and beverages. Finally, due to their unique 
mechanism of action, these stabilized essential oil emulsions can provide a long-term 
solution to the ever-increasing danger of antibiotic resistance. 
2.4. Experimental Protocol 
 
2.4.1 Materials and Methods 
All reagents and materials were purchased from Fisher Scientific and used as 
received. NIH-3T3 cells (ATCC CRL-1658) were purchased from ATCC. Dulbecco’s 
Modified Eagle’s Medium (DMEM) (DMEM; ATCC 30-2002) and fetal bovine serum 
(Fisher Scientific, SH3007103) were used in cell culture. Pierce LDH Cytotoxicity Assay 
Kit was purchased from Fisher Scientific. 
2.4.2 Synthesis of PONI-GAT 
Synthesis can be found under Supporting Figure 2.8. 
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2.4.3 Preparation of Nanocomposites 
Stock nanocomposite solutions were prepared in 0.6 ml Eppendorf tubes. To 
prepare the stock X-NC emulsions, 3 µL of carvacrol oil (containing 10 wt% p-MA-alt-
OD) was added to 497 µL of Milli-Q H2O (previously adjusted to a pH of 10) containing 
6 µM of PONI-GAT and emulsified in an amalgamator for 50 s. The non-crosslinked 
analogs were done in the same fashion however without p-MA-alt-OD dissolved in 
carvacrol. The emulsions were allowed to rest overnight prior to use. 
2.4.4 Fluorescamine Assay 
The fluorescamine calibration curve was generated by mixing various 
concentrations of PONI-GAT with fluorescamine (dissolved in acetonitrile – 2.5 mg/ml, 
50 µL aliquots) in phosphate buffer (PB – 5mM, pH = 7.4). The solutions were sonicated 
in the dark for 5 min, diluted with ethanol and their emission maxima at 470 nm analyzed. 
The percentage of amines remaining within the X-NCs at different wt% of p-MA-alt-OD 
was performed by diluting the stock emulsion solution by half. Afterwards, 450 µL of PB 
was added along with 50 µL of fluorescamine. The solutions were sonicated in the dark for 
5 min, diluted with ethanol and their emission maxima at 470 nm analyzed. 
2.4.5 Biofilm Formation 
Bacteria were inoculated in LB broth at 37°C until stationary phase. The cultures 
were then harvested by centrifugation and washed with 0.85% sodium chloride solution 
three times. Concentrations of resuspended bacterial solution were determined by optical 
density measured at 600 nm. Seeding solutions were then made in M9 to reach OD600 of 
0.1. 100 μL of the seeding solutions were added to each well of the microplate. M9 medium 
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without bacteria was used as a negative control. The plates were covered and incubated at 
room temperature under static conditions for a desired period. Planktonic bacteria were 
removed by washing with PB saline three times.  
Varied v/v % of X-NCs, made in M9 medium, were incubated with the biofilms for 3 
h. Biofilms were washed with phosphate buffer saline (PBS) three times and viability was 
determined using an Alamar Blue assay. M9 medium without bacteria was used as a 
negative control. 
2.4.6 Biofilm – 3T3 Fibroblast Cell Co-culture 
Fibroblast-3T3 coculture was performed using the previously reported protocol.28 
A total of 20,000 NIH 3T3 (ATCC CRL-1658) cells were cultured in Dulbecco's modified 
Eagle medium (DMEM; ATCC 30-2002) with 10% bovine calf serum and 1% antibiotics 
at 37oC in a humidified atmosphere of 5% CO2. Cells were kept for 24 hours to reach a 
confluent monolayer. Bacteria (P. aeruginosa) were inoculated and harvested as mentioned 
above. Afterwards, seeding solutions 108 cells/ml were inoculated in buffered DMEM 
supplemented with glucose. Old medium was removed from 3T3 cells followed by addition 
of 100 µL of seeding solution. The co-cultures were then stored in a box humidified with 
damp paper towels at 37oC overnight without shaking.  
Nanocomposites and other control solutions were diluted in DMEM media prior to 
use to obtain desired testing concentrations. Old media was removed from co-culture and 
replaced with freshly prepared testing solutions and was incubated for 3 hours at 37oC. Co-
cultures were then analyzed using an LDH cytotoxicity assay to determine mammalian cell 
viability using manufacturer’s instructions.51 To determine the bacteria viability in 
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biofilms, the testing solutions were removed, and co-cultures were washed with PBS. Fresh 
PBS was then added to disperse remaining bacteria from biofilms in co-culture by 
sonication for 20 min and mixing with pipet. The solutions containing dispersed bacteria 
were then plated onto agar plates and colony forming units were counted after incubation 
at 37oC overnight. 
2.5. Supporting Figures 
2.5.1 Shelf life of X-NC 
X-NCs were prepared as stated in the main text and allowed to stand for ~1 year. 
Afterwards, size was determined using dynamic light scattering (DLS) on a Zetasizer Nano 
ZS equipped with a He-Ne laser, 633nm. 
 
Figure 2.7. DLS size of X-NCs. The X-NCs maintained their integrity with an average 
diameter of 285 nm. 
 
2.5.2 Synthesis of PONI-GAT 
Br
NH3
Br
O
O O
O
O
DCM, Et3N, r.t 
overnight
Br
H
N
O
O
1  
Synthesis of 1. To a 500ml round bottom flask equipped with a stirbar was added 150ml 
of dichloromethane (DCM). Next, 3-Bromopropylamine hydrobromide (10.0g, 45.7mmol, 
1.0eq) was added to the DCM solution. Then, triethylamine (Et3N) (25.5ml, 182.7mmol, 
4.0eq) was added to the reaction mixture. Finally, Di-tert-butyl dicarbonate (12.6ml, 
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54.8mmol, 1.2eq) was added dropwise. After addition of di-tert-butyl dicarbonate, the 
reaction was stirred overnight at room temperature (r.t.). Afterwards, the DCM was 
rotovaped, diluted with 100ml of diethyl ether, and extracted with 1M HCL (1x 20ml), 
saturated sodium bicarbonate (2x 20ml), and brine (1x 20ml). The organic layer was dried 
with sodium sulfate, filtered, and rotovaped to yield 1 as a clear liquid. 1 was purified using 
column chromatography and silica gel as the stationary phase. 1H NMR (400MHz, CDCL3) 
4.6 (br, 1H) 3.43 (t, 2H), 3.26 (br, 2H), 2.04 (t, 2H), 1.43 (s, 9H). 
O
NH
O
O
Et2O, 100o C 
overnight 
Pressure Tube
O
OO N
H
2  
Synthesis of 2. In a pressure tube, furan (4.5ml, 61.7mmol, 1.5eq) and maleimide (4.0g, 
41.1mmol, 1.0eq) were added in addition to 5ml of diethyl ether. The tube was sealed and 
heated at 100oC overnight. Afterwards, the pressure tube was cooled to r.t. and the formed 
solid was removed, filtered, and washed with copious amounts of diethyl ether to isolate 2 
as a white solid and was used without further purification. 1H NMR (400MHz, MeOD) 
11.14 (s, 1H), 6.52 (s, 2H), 5.12 (s, 2H), 2.85 (s, 2H). 
O
OO N
H
2
1
K2CO3, KI, DMF 
50oC overnight
O
OO N
HN
OO
3  
Synthesis of 3. To a 100ml round bottom flask equipped with a stirbar was added 30ml of 
dimethylformamide (DMF). Next, 2 (2.36g, 14.3mmol, 1.0eq) was added along with 
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potassium carbonate (7.9g, 57.2mmol, 4.0eq). The reaction mixture was heated at 50oC for 
five minutes. Finally, potassium iodide (0.05g, 0.30mmol, 0.02eq) and 1 (3.47g, 14.6mmol, 
1.02eq) were added and stirred at 50oC overnight. Afterwards, the reaction mixture was 
cooled to room temperature, diluted to 150ml with ethyl acetate and washed with water 
(7x, 50ml) and brine (1x, 50ml). The organic layer was dried with sodium sulfate, filtered, 
and rotovaped to yield 3 as a white solid. 3 was purified using column chromatography and 
silica gel as the stationary phase. 1H NMR (400MHz, CDCL3) 6.51 (s, 2H), 5.26 (s, 2H), 
5.03 (br, 1H), 3.56 (t, 2H), 3.05 (q, 2H), 2.86 (s, 2H), 1.73 (quint, 2H) 1.45 (s, 9H). 
O
OO N
HN
OO
TFA, DCM (1:1)
r.t. 2 h
O
OO N
H3NO
O
F
F F
3
4
 
Synthesis of 4. To a 50ml round bottom flask equipped with a stirbar was added 3 (2.0g, 
6.2mmol, 1.0eq). Nitrogen was bubbled through DCM for five minutes and 5ml was added 
to the flask which was purged with nitrogen. 5ml of trifluoroacetic acid (TFA, excess) was 
added and the reaction was stirred for two hours. Afterwards, excess TFA was removed by 
rotovaping with DCM (3x) yielding 4. 4 was isolated as a white solid by washing with 
diethyl ether (3x, 10ml) and used without further purification and directly used in the next 
reaction (Ninhydrin test confirms free primary amine). 
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O
OO N
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F F
N N
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H
O
O
O
O
Et3N, MeCN/H2O (9:1) 
r.t. overnight
O
OO N
HN
NHN
OO
O
O
4
5  
Synthesis of 5. To a 100ml round bottom flask equipped with a stirbar was added 4 (1.2g, 
3.6mmol, 1.0eq), 45ml acetonitrile (MeCN), and 5ml of water. Triethylamine (4.7ml, 
33.5mmol, 9.2eq) was added and finally N,N′-Di-Boc-1H-pyrazole-1-carboxamidine 
(1.7g, 5.5mmol, 1.5eq) in portions. The reaction was allowed to stir at r.t. overnight. 
Afterwards, the solution was diluted with 100ml of ethyl acetate and extracted with water 
(2x, 50ml) and brine (2x, 50ml). The organic layer was dried with sodium sulfate, filtered, 
and rotovaped to yield 5. 5 was purified using column chromatography and silica gel as the 
stationary phase to yield a white solid. 1H NMR (400MHz, CDCL3) 8.49 (t, 1H), 6.49 (s, 
2H), 5.25 (s, 2H), 3.53 (t, 2H), 3.47 (q, 2H), 2.83 (s, 2H), 1.82 (quint, 2H), 1.49 (s, 18H). 
 
O
O
O
O
OH
CBr4, PPh3
MeCN, 0oC - 5min 
r.t. - overnight
O
O
O
O
Br
6  
Synthesis of 6. To a 250ml round bottom flask was added Tetraethyleneglycol 
monomethyl ether (4.2ml, 20.9mmol, 1.0eq) and 80ml of MeCN. The reaction was cooled 
to 0oC and tetrabromomethane (8.4g, 25.1mmol, 1.2eq) was added. Finally, 
triphenylphosphine (6.6g, 25.3mmol, 1.2eq) was added in portions and allowed to stir for 
five minutes at 0oC. After five minutes, the reaction was warmed to room temperature and 
stirred overnight. Afterwards, the reaction was concentrated by rotovaping and purified 
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using column chromatography and silica gel as the stationary phase to yield 6 as a clear oil 
(Potassium permanganate was used to visualize 6). 1H NMR (400MHz, CDCL3) 3.75 (t, 
2H), 3.6 (br, 10H), 3.49 (t, 2H), 3.41 (t, 2H), 3.32 (s, 3H).
O
O
O
O
Br
6
2
K2CO3, KI, DMF 
50oC overnight
O
OO N
O
O
O
O
7
 
Synthesis of 7. To a 100ml round bottom flask equipped with a stirbar was added 30ml of 
DMF. Next, 2 (2.84g, 17.2mmol, 1.0eq) was added along with potassium carbonate (9.48g, 
68.7mmol, 4.0eq). The reaction mixture was heated at 50oC for five minutes. Finally, 
potassium iodide (0.05g, 0.30mmol, 0.02eq) and 6 (4.9g, 18.0mmol, 1.05eq) were added 
and stirred at 50oC overnight. Afterwards, the reaction mixture was cooled to room 
temperature, diluted to 150ml with ethyl acetate and washed with water (7x, 50ml) and 
brine (1x, 50ml). The organic layer was dried with sodium sulfate, filtered, and rotovaped 
to yield 7. 7 was isolated as a clear oil using column chromatography and silica gel as the 
stationary phase. 1H NMR (400MHz, CDCL3) 6.49 (s, 2H), 5.23 (s, 2H), 3.66 (t, 2H), 3.6 
(br, 8H), 3.58 (br, 4H), 3.51 (t, 2H), 3.35 (s, 3H), 2.83 (s, 2H). 
 
O
OO N
HN
NHN
OO
O
O
O
OO N
O
O
O
O
+
1) DCM, 12 min, r.t.
2) Ethyl Vinyl Ether
O O
O ON OO N
HN
NN
H
n
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O O
O
O
O
OO N
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OO
+
O
OO N
k
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O O
O
O
O
O735  
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Synthesis of Polymer 8. To a 10ml pear-shaped flask equipped with a stirbar was added 5 
(457mg, 0.98mmol, 1.0eq), 3 (317mg, 0.98mmol, 1.0eq) and 7 (300mg, 0.84mmol, 0.85eq) 
along with 5ml of DCM. In a separate 10ml pear-shaped flask equipped with a stirbar was 
added Grubbs Catalyst 3rd Generation (38.4mg, 0.043mmol, 0.04eq) along with 1ml of 
DCM. Both flasks underwent freeze-pump thaw three times, warmed to room temperature 
and the catalyst transferred to the reaction mixture. After 12 minutes, ethyl vinyl ether 
(200µl, excess) was quickly added and stirring continued for 15 minutes. The polymer was 
precipitated using 200ml of 1:1 hexane:ethyl ether. The polymer was collected by filtration, 
dissolved in a minimal amount of DCM and precipitated again in the same hexane:ethyl 
ether solution yielding 8 as a gray solid. MW = 31,736 (MW was determined through gel 
permeation chromatography (tetrahydrofuran) with a polystyrene calibration curve). 1H 
NMR (400MHz, CDCL3) 11.4 (s, 1H), 8.39 (br, 1H), 6.01 (s, 2H), 5.72 (br, 2H), 4.95 (br, 
2H), 4.41 (br, 2H), 3.55 (br, 11H), 3.32 (br, 2H), 3.30 (s, 2H), 3.29 (br, 2H), 3.01 (br, 1H), 
1.82 (br, 1H), 1.7 (br, 3H), 1.42 (s, 12H), 1.35 (s, 6H). 
 
 
 
Synthesis of Polymer 9 – PONI-GAT. To a 50ml round bottom flask equipped with a 
stirbar was added Polymer 8 (400mg). Dichloromethane was purged with nitrogen for five 
minutes and 12ml was added to the flask, sealed with a septum and purged with nitrogen 
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for five minutes. The main nitrogen line was left in the septum and the nitrogen pressure 
was reduced to a steady stream. 12ml of trifluoroacetic acid (excess) was added and the 
reaction was allowed to stir for two hours. Afterwards, excess TFA was removed by 
rotovaping with DCM (3x). The reaction residue was dissolved in a minimal amount of 
water, filtered through a polyethersulfone (PES) syringe filter and lyophilized to yield 9 as 
an off-white solid which readily dissolves in water. MW ~ 23,486. 1H NMR (400MHz, 
D2O) 6.1 (br, 2H), 5.91 (br, 2H), 5.2 (br, 2H), 4.64 (br, 2H), 3.65 (br, 19H), 3.39 (s, 2H), 
3.21 (br, 2H), 3.01 (br, 2H), 1.99 (br, 2H), 1.89 (br, 2H) (1H NMR confirms complete loss 
of all Boc protecting groups). 
 
Figure 2.8. 1HNMR spectra of a) protected and b) deprotected PONI-GAT. 
 
2.5.3 Zeta Potential 
Zeta potential of the X-NCs were performed on a Zetasizer Nano ZS equipped with 
a DTS1070 cuvette. 
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Figure 2.9. Zeta potential of X-NCs with varying wt% of p-MA-alt-OD. Results show a 
highly negative charged nanocomposite regardless of p-MA-alt-OD present. 
2.5.4 Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy (ATR-
FTIR) 
ATR-FTIR was performed on a Bruker Alpha FT-IR spectrophotometer fitted with 
a Platinum ATR QuickSnap sampling module. Freeze-dried samples of X-NCs along with 
p-MA-alt-OD and PONI-GAT were analyzed to determine changes in functional groups 
before and after emulsification. 
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Figure 2.10. ATR-FTIR analysis before and after emulsification. Results showed complete 
loss of anhydrides on p-MA-alt-OD (1857 cm-1, 1776 cm-1) followed by the formation of 
carboxylate frequencies (3300 cm-1, 1564 cm-1) and amide frequencies (1650 cm-1) 
supporting crosslinking between the amines of PONI-GAT and the anhydrides on p-MA-
at-OD. 
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Figure 2.11. Fluorescamine calibration curve. A reaction between the amines on PONI 
GAT with fluorescamine generates a fluorescence signal. 
 
2.5.5 Serum Stability of Non-Crosslinked NCs 
 
Figure 2.12. DLS size of a) 10% fetal bovine serum only and b) non-crosslinked 
nanocomposites. The non-crosslinked emulsion is immediately disrupted leaving only 
serum proteins present. 
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CHAPTER 3 
DYNAMICALLY CROSSLINKED POLYMER 
NANOCOMPOSITES TO TREAT MULTIDRUG-
RESISTANT BACTERIAL BIOFILMS 
 
 
3.1. Introduction 
Multidrug-resistant (MDR) bacterial biofilms are widely found in wounds, 
indwelling medical devices, and dead tissue fragments.1 It is reported over 80% of all 
human infections are due to biofilms, such as osteomyelitis, chronic bacterial prostatitis, 
and chronic otitis media.2-4 Biofilms are extremely refractory to antimicrobial treatment 
and easily evades the hosts immune responses.5,6 Currently, aggressive antibiotic 
treatments coupled with debridement (removal of infected tissue and limbs) is the best 
therapeutic intervention for biofilms. However, this approach fails to fully eradicate 
biofilms,7 and has considerable drawbacks including increased patient suffering, health 
care costs, and accumulative drug resistance.8,9 Hence, it is urgent to develop alternative 
therapeutic platforms that can eliminate these dangerous infections.  
Phytochemical extracts, components isolated from trees and plants, have been 
previously used as natural antimicrobial agents.10,11 However, their lack of solubility and 
stability in physiological environments limit their practical use.12,13 Stabilizing these oils 
with surfactants or nanoparticles to generate emulsions can improve their solubility in 
aqueous environments and antimicrobial activity against bacteria.14,15 However, long-term 
mechanical stability and potentially adverse mammalian cell toxicity limit their therapeutic 
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practicality.16 Covalently crosslinking the emulsions can dramatically improve their 
stability in serum-containing conditions while maintaining high antimicrobial efficacy.17 
However, this crosslinking strategy does not incorporate degradable linkage sites and may 
cause accumulation of the antimicrobial system in the body if used long-term.18 
 
Figure 3.1.  a) Schematic depiction of the strategy used to generate DCPNs along with the 
chemical structures of ATA crosslinker and PONI-GAT; b) TEM micrograph of DCPNs. 
Scale bar is 100 nm; c) DLS histogram indicating the size distribution of DCPNs in 
phosphate buffer saline (PBS, 150 mM). 
 
 
Taking advantage of the acidic microenvironments within biofilms we set out to 
develop degradable analogues of our previously reported composites. Herein, we describe 
the design and therapeutic applicability of dynamically crosslinked polymer 
nanocomposites (DCPNs). DCPNs fabrication is based on spatial-directed crosslinking 
derived from in situ Schiff-base reactions (Figure 3.1). An adamantyl-core tetrakisaldehyde 
(ATA) was used as the crosslinker. The adamantyl core has excellent solubility in 
hydrophobic solvents and contains reactive aldehyde groups to bridge amino-
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functionalized polymers used to stabilize the oil composite.19,20 We hypothesized ATAs 
would make a suitable polymer crosslinker and produce pH responsive imine bonds 
throughout and at the oil-water interface of the emulsion. Furthermore, these composites 
are envisioned to degrade over-time after the antimicrobial payload has been released. We 
demonstrate DCPNs have good serum stability and shelf-life and easily penetrates the 
extracellular polymeric substance (EPS) matrix, eliminating enclosed MDR bacteria. 
Taken together, the therapeutic properties of DCPNs make them promising candidates to 
treat wound biofilm infections. 
 
3.2. Results 
3.2.1 Generation and Characterization of DCPNs 
As shown in Figure 3.1., a poly(oxanorborneneimide) scaffold bearing guanidine, 
amino, and tetraethylene glycol monomethyl ether groups (PONI-GAT), an adamantyl-
based crosslinker ATA, and carvacrol oil are used to generate the antimicrobial 
nanocomposites. The synthesis and characterization of PONI-GAT has been described 
previously.17 The synthesis of ATA was carried out following the modified procedures,23,24 
and it was characterized using 1HNMR and ATR-FTIR (Supporting Figure 3.7, Supporting 
Figure 3.8). The nanocomposites were prepared by emulsifying ATA-containing carvacrol 
oil（DCPN）or carvacrol oil only (Non-crosslinked control, PN) in a water solution which 
contains PONI-GAT. The pH of the aqueous solution was pre-adjusted to around 10, so 
that the amines on PONI-GAT are nucleophilic towards ATA aldehydes. Upon 
emulsification, PONI-GAT acts as a stabilizer and assembles at the oil-water interface of 
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the oil droplets. In the presence of ATA, PONI-GAT amines crosslink with ATA 
aldehydes, generating DCPNs. The morphology and size of DCPNs were characterized 
with transmission electron microscopy (TEM) and dynamic light scattering (DLS), 
indicating they are spherical-shaped particles with an average size of ~220nm. ATR-FTIR 
spectrum of freeze dried DCPNs indicated a complete loss of aldehydes from ATA and 
formation of imines (Supporting Figure 3.9), demonstrating successful Schiff-base 
crosslinking. To provide more insight into the Schiff base crosslinking, hydroxylamine 
(HA, possessing much higher equilibrium constant with benzaldehyde group than that of 
alkyl amine) was used as a competitive molecule to despoil the benzaldehyde groups 
reacted with amino groups in DCPNs. DLS results show that the DCPNs becomes unstable 
after incubating with hydroxylamine for 1h, with obvious aggregation after 3h (Supporting 
Figure 3.10). However, the control samples with only PBS do not show a size change. 
These results further support that Schiff base crosslinking is responsible for DCPN 
stability. 
We next probed the morphological structure of DCPNs using CSLM. The 
formulation was modulated to generate micron-sized analogues that are easily seen under 
CSLM. PONI-GAT was partially labelled with TRITC (red fluorescence) and emulsified 
with the ATA-containing oil loaded with 3,3-Dioctadecyloxacarbocyanine (DiO, green 
fluorescence). As shown in Figure 3.2, the confocal images demonstrate a co-localization 
of red and green fluorescence, indicating DCPNs adopt a composite morphology as 
opposed to a core-shell structure. A composite morphology is plausible given PONI-GATs 
amphiphilic properties and its loss of hydrophilicity as it reacts with hydrophobic ATAs. 
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Figure 3.2. Confocal micrographs of the corresponding micron-sized counterparts of 
DCPNs. PONI-GAT was partially labelled with TRITC (red fluorescence), and the oil core 
is loaded with DiO (green fluorescence). The results show that red fluorescent PONI-GAT 
can be seen colocalized with the green fluorescent oil core, indicating a composite (as 
opposed to core-shell) morphology. 
 
 
3.2.2 Stability and pH Responsiveness of DCPNs 
Nanoemulsion stability in serum media is vital for biomedical applications.25,26 An 
ideal antimicrobial therapeutic platform should be stable enough to maintain its 
antimicrobial payload both during storage and delivery, while readily dissociating and 
releasing its payload at the infection site. We further characterized DCPNs and determined 
its structural integrity in aqueous environments. We hypothesized that DCPNs with imine 
crosslinking would have suitable stability in the presence of high ionic strength and serum 
environments, while losing stability in the presence of acidic environments.27 Therefore, 
we monitored the stability and dissociation of DCPNs using DLS. A series of DCPN 
samples with increasing amounts of ATA were fabricated and their size monitored after 
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incubation with 10% fetal bovine serum (FBS) for 6h (Supporting Figure 3.11). It is 
observed that the stability of DCPN increases with increasing concentrations of ATA, with 
a 5wt% ATA loading showing no evidence of destabilization/aggregation.  In stark contrast 
to non-crosslinked PNs which had no stability in serum (Figure 3.3a), DCPNs maintained 
stability in serum within the time duration of our studies. A 5wt% loading of ATA within 
the oil core was chosen as the optimized formulation. Afterwards, we monitored the size 
of optimized DCPNs in PBS media at different pH conditions. As shown in Figure 3.3b, 
we observed DCPNs displayed high stability under physiological conditions (pH=7.4). 
Furthermore, DCPN samples demonstrated long-term stability in these conditions even 
after 6 months of storage. (Supporting Figure 3.12). However, the size of DCPN was 
compromised at pH=6.5, with further instability observed when the pH was decreased to 
5. The DLS results indicate that DCPNs are sufficiently stable in physiological conditions 
yet become unstable in acidic conditions. According to previous literature, the average 
biofilm infection pH has been observed to be ~ 5.5.28 At these conditions, DCPNs within 
biofilms would theoretically dissociate, simultaneously addressing vehicle degrading and 
payload release (Figure 3.3c).  
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Figure 3.3. a) DLS curves of DCPNs. NonPNs and serum media are only in 10% fetal 
bovine serum (FBS); b) DLS curves of DCPN with different pH in PBS; c) Proposed 
antibiofilm mechanism. 
 
 
3.2.3 DCPNs Penetration into Biofilm 
Antimicrobial penetration into biofilms is essential for biofilm eradication.29 With 
DCPNs size, morphology, and stability characterized, we next probed DCPNs ability to 
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penetrate biofilms using confocal microscopy. DiO was again loaded into DCPNs oil core 
and used to track their delivery into biofilms formed by red fluorescent protein (RFP) 
expressing Escherichia coli. DCPNs were incubated with biofilms for 1 h, washed, and 
their penetration analysed using ImageJ software. As illustrated in Figure 3.4, the 
fluorescence overlay shows DCPNs are distributed throughout the entire biofilm, 
colocalizing with the enclosed bacteria. The results indicate DCPNs are suitable carriers 
for antimicrobial payloads that can be delivered efficiently to biofilms.  
 
 
Figure 3.4. Representative 3D views of confocal image stacks of RFP-expressing DH5-α 
E. coli biofilms. DiO-loaded DCPN and their overlay after treating the biofilm for 1 h with 
5wt% DiO-Loaded DCPN at 5% (v/v%) concentration in M9 media. 
 
 
3.2.4 DCPNs Antibiofilm Activity 
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Having validated DCPNs ability to penetrate a biofilm matrix, we next evaluated 
their antimicrobial activity against multiple Gram-negative and positive bacteria in their 
plankton or biofilm state. First, we determined the minimum inhibition concentrations 
(MIC) against a library of bacteria. DCPNs demonstrate MIC values ranging from 0.74-
1.50 mM (Supporting Table 3.1). In addition to MIC, we investigated the structural 
integrity of Gram-negative and positive planktonic species using scanning electron 
microscopy (SEM) after 3 h incubation with DCPNs (Figure 3.13). In contrast to untreated 
bacteria, bacteria treated with DCPNs showed obvious cell wall/membrane damage along 
with a reduction in bacteria populations. Afterwards, four pathogenic bacterial strains of 
clinical isolates, Pseudomonas aeruginosa (P. aeruginosa, CD-1006), Enterobacter 
cloacae (E. cloacae, CD-1412) complex, Escherichia coli (E. coli, CD-2), and a 
methicillin-resistant strain Staphylococcus aureus (S. aureus, CD-489, MRSA) were 
chosen to test DCPNs antibiofilm properties. As shown in Figure 3.5, biofilms treated with 
DCPNs for three hours were effectively eliminated at a concentration of 4 v/v% (1.50 mM 
carvacrol oil). Notably, Gram-negative (CD-1006, CD-2, CD-1412) and positive (CD-489) 
bacterial biofilms can be treated, demonstrating DCPNs have broad-spectrum activity. 
Compared to the individual components of DCPN as control samples, DCPN exhibited 
significantly higher antibiofilm activity than that of pure carvacrol oil or PONI-GAT, 
supporting our antibiofilm mechanism proposed in Figure 3.3c.  
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Figure 3.5. Viability of 1-day-old biofilms. (a) P. aeruginosa (CD-1006), (b) E. coli (CD-
2), (c) En. cloacae complex (CD-1412) and (d) S. aureus (CD-489) biofilms after 3-hour 
treatment with 5wt% DCPN, PONI-GAT only, and Carvacrol oil only at different 
antimicrobial concentrations (mM)/ (v/v %). The data are average of triplicates, and the 
error bars indicate the standard deviations. 
 
 
3.2.5 Cytotoxicity Assessment of DCPNs Against Fibroblast Cells 
Finally, we investigated the cytotoxicity of DCPN to mammalian NIH 3T3 (ATCC 
CRL-1658) Fibroblast cells. Fibroblasts are critical in rebuilding the structural framework 
in animal tissues during wound healing processes.30 We incubated fibroblast cells with 
DCPNs using the same experimental conditions as used for biofilms. As shown in Figure 
3.6, no observable cytotoxicity to Fibroblast cells at 4 v/v % of DCPN was observed. Given 
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that DCPNs successfully eliminate both Gram-negative and positive biofilms below this 
concentration, the results suggest that DCPNs are promising candidates to eliminate 
pathogenic biofilms in the presence of mammalian cells, a critical need in wound therapy. 
 
Figure 3.6. Viability of 3T3 fibroblast cells after treated with 5wt% DCPN at different 
emulsion concentrations for three hours. Each result is an average of five experiments, and 
the error bars designate the standard deviations. 
 
3.3. Conclusions 
In conclusion, we have developed a dynamically crosslinked polymeric 
nanocomposite that demonstrates promise as an MDR biofilm therapeutic. Taking 
advantage of the dynamic scaffold presented within DCPNs, the nanoemulsions 
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demonstrated good stability in physiological conditions while readily degrading in acidic 
conditions found commonly in biofilm infections.  Furthermore, DCPNs are broad-
spectrum antimicrobials that effectively penetrate and eliminate enclosed pathogens within 
biofilms at concentrations that do not compromise fibroblast cell viability. Given the oil 
core is a suitable environment to encapsulate a range of other hydrophobic antimicrobials 
and drugs, we envision future degradable antimicrobial emulsions can build off this 
strategy, potentially providing potent therapeutic platforms to fight against the rising 
number of MDR biofilm infections in biomedical settings. 
 
3.4. Experimental Protocols 
3.4.1 Chemicals and Reagents 
Titanium tetrachloride (99.9%), Dichloromethyl methylether, Hydroxylamine 
(50wt% in water) were purchased from Sigma Aldrich, all the other reagents and materials 
were purchased from Fisher Scientific and used as received. NIH-3T3 cells (ATCC CRL-
1658) were purchased from ATCC. Dulbecco’s modified Eagle’s medium (DMEM; ATCC 
30-2002) and fetal bovine serum (Fisher Scientific, SH3007103) were used in cell culture. 
The Pierce LDH cytotoxicity assay kit was purchased from Fisher Scientific. 
3.4.2 Fabrication of DCPNs 
Stock nanocomposite emulsions were prepared in 0.6 mL Eppendorf tubes. To 
prepare the stock DCPN emulsions, 3 μL of carvacrol oil (containing 5 wt% ATA) was 
first added to a 0.6 mL Eppendorf tube, then a 20 μL (150μM) PONI-GAT solution was 
added into the tube, followed by 477 μL of Milli-Q H2O (previously adjusted to a pH of 
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10) and emulsified in an amalgamator for 50s. The non-crosslinked analogue (Non-PN) 
was generated in the same fashion, however without ATA dissolved in carvacrol. The 
emulsions were allowed to rest overnight prior to use. 
3.4.3 MIC Measurements 
Bacteria were inoculated in LB broth in a shaker at 275 rpm and 37 °C until they 
reached stationary phase. The cultures were then harvested by centrifugation and washed 
with 0.85% sodium chloride solution three times. The concentrations of resuspended 
bacterial solution were determined by optical density measured at 600 nm. MICs of DCPNs 
against all bacteria were determined by the microdilution method reported previously with 
slight modifications.21 Briefly, the DCPNs emulsions were serially diluted with M9 to 
various concentrations (64-0.5) v/v%. The bacterial suspension was diluted in M9 broth to 
a final concentration of 106 CFU mL−1.  Equal volumes (50 μL) of microbial suspension 
and DCPNs solution with varied concentrations were mixed in each well of a 96-well plate. 
Thus, the final concentration of bacteria in each well was 5 × 105 CFU mL−1 and those of 
DCPN emulsions were 32-0.25 v/v %, respectively. M9 broth containing only microbial 
cells was used as the negative control, and M9 broth only as the growth control. Each test 
was performed in three replicates. The plates were then incubated in a shaker at 275 rpm 
and 37 °C overnight and their optical density was measured at 600 nm. The MIC values 
were reported as the lowest concentration of the antimicrobial to inhibit the visible growth 
of bacteria.  
3.4.4 Antibiofilm Activity Measurements 
Bacteria seeding solutions were made in M9 to reach 0.1 OD (108 CFU mL-1). 100 
μL portions of the seeding solutions were added to each well of the microplate. M9 medium 
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without bacteria was used as a negative control. The plates were covered and incubated at 
room temperature under static conditions. The biofilms were used after 1 day. Biofilms 
were washed with PBS (three times) to remove the planktonic bacteria. Next, varied 
concentration of DCPNs, made in M9 medium, were added to each well of the microplate. 
The microplate was then incubated at 37oC under static conditions. After 3 h, biofilms were 
washed with PBS three times, and the viabilities were determined using Alamar Blue assay 
according to the manufacturer’s protocol.  
3.4.5 Cytotoxicity Evaluation of DCPNs Against Fibroblast Cells 
NIH 3T3 cells (ATCC, Manassas, VA, U.S.A) were cultured in Dulbecco’s 
modified Eagle’s medium supplemented with 4.5g/L glucose, 10% FBS and 1% antibiotics 
(100 U/mL penicillin and 100 μg/mL streptomycin). Cells were maintained at 37°C in a 
humidified atmosphere containing 5% CO2. Cells were regularly passaged by 
trypsinization with 0.25% trypsin with EDTA, (Invitrogen) in PBS (pH 7.4). At ~80% 
confluence, cells were trypsinized and seeded in a 96-well plate at a density of 20,000 cells/ 
well. After allowed to attach overnight, cells were washed by PBS and treated with desired 
concentration of DCPNs for 3 h. At the end of treatment, the cell viability was measured 
using a Pierce LDH Cytotoxicity Assay Kit (Thermo Fisher Scientific). Procedures were 
performed according to manufacturer’s instruction. 
3.4.6 TEM, Dynamic Light Scattering (DLS), Confocal Scanning Laser Microscopy 
(CSLM), and SEM Methods 
The samples for TEM were prepared by dropping 5 μL of the DCPNs emulsion 
onto Formvar Film on 300 Square Mesh, Nickel Grids (EMS FF300-Ni). The TEM images 
were taken on a JOEL 2000FX TEM instrument at an acceleration voltage of 200 kV. DLS 
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measurements were performed on a Malvern NanoZS apparatus operating at a 173-degree 
scattering angle. The CSLM experiments both for the DCPNs morphology and their 
penetration into biofilms were performed on a Nikon A1 Resonant scanning confocal 
microscope. SEM was carried out according to modified procedure. [22] 2 ml 0.1 OD (108 
CFU mL-1) bacterial suspension in M9 media was incubated with 4v/v% DCPNs at 37oC 
for 3h. The bacteria were collected by centrifugation at 1,200 rpm for 10 min and washed 
twice using PBS (pH=7.4), and then made a thin smear on a silica wafer. Glutaraldehyde 
solution (2.5% in PBS) was used to fix the bacteria cells at 4oC overnight. After rinsing 
three times using PBS, the samples were dehydrated by ethanol in a gradient alcohol 
concentration (25%, 50%, 75%, 90%, and 100%). Finally, after sputter coating with gold 
for 1 min, the samples were observed in FEI Magellan 400 field emission scanning electron 
microscope operated at 1 kV with 13 µA of beam current. Control samples without 
treatment were also prepared and tested in the same way as mentioned above. 
3.4.7 Evaluate DCPNs Imine Bond Displacement 
The crosslinking of DCPNs through imine bonds was further observed using an 
imine-oxime displacement reaction. 10μL hydroxylamine solution was added to 50 μL 
DCPNs stock and mixed. Then the bottles were placed on an orbital shaker (1200 rpm) at 
room temperature for 1h and 3h, respectively. The control samples were also prepared in 
the same method except using PBS instead of hydroxylamine. The size of both control and 
treated samples were measured by DLS. 
 
3.5. Supporting Figures 
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3.5.1 Synthesis and Characterization of Crosslinker 1,3,5,7-Tetrakis(4-formylphenyl
）adamantane (ATA) 
Br
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Synthesis of 1. To a 150 mL three-neck flask equipped with a reflux condenser, a calcium 
chloride drying tube, and magnetic stir-bar, 1-bromoadamantane (5.0 g, 23.0 mmol, 1.0 
eq), tert-butyl bromide (6.3 g, 46.0 mmol, 2 eq), and benzene (50 ml, 560 mmol, 560.0 eq) 
was added and allowed to stir at 55oC for 10 min. Then, aluminum chloride (0.6 1g, 4.60 
mmol, 0.2 eq) was added slowly and the reaction solution was heated and stirred under 
vigorous reflux for 1 hour. Afterwards, the system was then poured into ice water and ether 
was then added into the mixture while stirring. The resulting undissolved substance was 
filtered and vacuum dried followed by Soxhelt purification in chloroform for 48 hours. 
After vacuuming dry, 1 was obtained as white powder and carried directly to the next step. 
Synthesis of 2. Following a modified literature procedure, to a 250 mL three-neck round-
bottom flask equipped with a magnetic stir-bar, 1 (3.8 g, 8.6 mmol, 1.0 eq) and 150 mL 
dichloromethane was added. Under a continuous flow of nitrogen, the mixture was stirred 
rapidly and cooled to -10oC with an ice/salt bath. Afterwards, titanium tetrachloride (19.0 
mL, 172.4 mmol, 20.0 eq) was added slowly to the mixture and stirred at -10oC for 30 min. 
Then, dichloromethyl methylether (12.5 mL, 137.9 mmol, 16.0 eq) was subsequently added 
dropwise to the mixture. The reaction was held at -10oC for 3 hours and then allowed to 
warm to room temperature and stirred overnight. The mixture was poured into 300 mL ice-
water, and 100 mL of 1 M HCl was added and allowed to stir for 30 minutes. The two-
phase mixture was separated, and the aqueous phase was washed twice with 100 mL DCM. 
The combined organic phases were successively washed with saturated aqueous NaHCO3 
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and saturated NaCl and then dried with Na2SO4. The solution was filtered, and the solvent 
removed with a rotavapor. The resultant yellow solid was purified by column 
chromatography and then recrystallized from dioxane to give ATA as white crystals. 
 
 
Figure 3.7. 1HNMR spectrum of ATA with CDCl3 as the solvent. 1H NMR (400 MHz, 
CDCl3): δ (ppm) 10.02 (s, 4H), 7.91 (d, 8H), 7.67 (d, 8H), 2.26 (s, 12H).  
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Figure 3.8. Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy (ATR-
FTIR) spectrum of ATA. ATR-FTIR(cm-1): 3029 (Phenyl, C-H); 2928 (Adamantyl, CH2); 
2852, 2738 (CHO, CH); 1697 (C=O); 1601, 1571 (Phenyl ring).    
 
3.5.2 Synthesis and Characterization of DCPNs 
Freeze-dried samples of DCPN along with the non-crosslinked counterparts 
(NonPN) as the control samples were analyzed using ATR-FTIR. 
4000 3500 3000 2500 2000 1500 1000
0
20
40
60
80
100
C-N
Tr
an
sm
itt
an
ce
 [%
]
Wavenumber [cm-1]
 DCPN
 nonPN
No CHO peaks
C=N
 
Figure 3.9. ATR-FTIR spectra of DCPN and NonPN. The results show that the aldehyde 
groups (2852, 2738 cm-1) from crosslinker ATA are lost, and imine bonds (C=N,1605 cm-
1; C-N,1173cm-1) formed within DCPN. 
 
3.5.3 Dynamic Light Scattering (DLS) of DCPNs 
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Figure 3.10. DLS curves monitoring imine – oxime displacement in PBS. DCPNs were 
incubated with the imine-displacing reagent hydroxylamine (HA) for the indicated 
durations. DCPNs size is compromised in the presence of HA, indicating PONI-GAT no 
longer provides stability and results in composite aggregation. 
 
 
Figure 3.11. Variation of DLS curves detected after incubated half an hour in serum media 
for DCPN. The results show that the DCPN stability increases with the crosslinker content 
until 5wt%, so the 5wt% was chosen as the optimal crosslinker content in this study. 
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Figure 3.12. DLS curves monitoring the shelf life of DCPN and the NonPN control. Both 
the DCPN and NonPN were prepared as stated in main text and allowed to stand for 
6months within our studied range, The DLS curves were obtained by detecting the same 
sample after 24h and 6 months, respectively. The results illustrate that DCPN has 
significantly improved storage stability than the non-crosslinked analog. 
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Figure 3.13. SEM micrographs of pathogenic planktonic bacteria. E. coli and S. aureus 
were incubated either with M9 only (control) or 4 v/v% DCPNs (treated) for 3 h. Treated 
samples show a reduction in bacteria population and compromised bacterial cell 
walls/membranes. 
 
 
Table 3.1. MICs of the 5wt%DCPN against different strains of bacteria 
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CHAPTER 4 
BIODEGRADABLE NANOCOMPOSITE 
ANTIMICROBIALS FOR THE ERADICATION OF 
MULTIDRUG-RESISTANT BACTERIAL BIOFILMS 
WITHOUT ACCUMULATED RESISTANCE 
 
 
4.1. Introduction 
Multidrug-resistant (MDR) bacteria infect more than two million people annually 
in the U.S., resulting in significant loss of life and limb, with treatment requiring prolonged 
and costly therapeutic regimens.1,2,3 These dangerous pathogens, including P. aeruginosa 
and S. aureus, further frustrate treatment due to their innate ability to micro-colonize into 
biofilms.4,5,6 Bacterial biofilm infections are challenging to treat on wounds and indwelling 
medical devices, as the extracellular polymeric substances (EPS) in these biofilms both 
inhibit antibiotic penetration and aid bacteria to evade host immune responses.7,8,9 
Furthermore, the slow growth rate of bacteria and the biofilm microenvironment act 
together  to facilitate  the development of antibiotic resistance.10,11,12 The emerging threat 
of antibiotic resistant biofilm infections has triggered an international push to develop 
alternative therapeutic platforms capable of eliminating these infections.13,14  
Plant-derived phytochemicals have emerged as an alternative to traditional 
antibiotic paradigms to combat MDR bacteria,15,16,17,18,19 providing a potential strategy for 
avoiding antibiotic tolerance and horizontal gene transfer that dramatically accelerate 
acquisition of drug resistance.20,21 Phytochemicals feature low cost,22 biocompatibility,23 
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and can be effective towards bacterial infections.24 However, the poor solubility of these 
hydrophobic oils in aqueous media limit their practical application as antimicrobial 
agents.25 Surfactant, nanoparticle, and polymer additives aid in phytochemical delivery by 
forming oil-in-water emulsions.26,27,28,29 Furthermore, crosslinking of these emulsions have 
demonstrated phytochemical stability in even complex media such as serum.30 However, 
such crosslinking strategies are non-biodegradable and may persist and accumulate within 
the body, causing unwanted side effects, such as inflammation and carcinogenesis.31,32,33 
Here, we report crosslinked poly(oxanorborneneimide)-stabilized oil-in-water 
nanocomposites (X-BNCs) engineered to be biodegradeable in the presence of endogenous 
biomolecules such as glutathione and esterase enzymes (Figure 4.1). These ‘nanosponges’ 
incorporate disulfide34 and ester35,36 crosslinkers that provide long-term stability in aqueous 
environments while facilitating nanocomposite degradation in biological milieus. We 
demonstrate the loading of these X-BNCs with carvacrol to provide therapeutics that 
eradicate Gram negative/positive bacteria including MDR strains. These nanocomposites 
are stable in serum-containing media, however degrade rapidly in the presence of 
glutathione or esterase proteins. The potential of X-BNCs as a wound healing therapeutic 
was demonstrated in an in vitro coculture with biofilms grown on top of mammalian 3T3 
fibroblast cells. A 4-log reduction in bacterial colonies was observed with no change in 
fibroblast cells viability. In stark contrast to antibiotics, X-BNCs do not evoke resistance 
in bacteria, maintaining their potency against pathogenic E. coli (CD-2) in a 20-cycle serial 
passage study. Taken together, the efficacy, biodegradability, and stability of these anti-
biofilm agents coupled with their lack of resistance accumulation make them a promising 
therapeutic platform to combat the rising dangers of MDR bacterial infections. 
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Figure 4.1. (a) Crosslinked PONI-GMT–DTDS structure showing linkage points reactive 
to endogenous biomolecules. (b) DLS histogram of crosslinked PONI-GMT–DTDS 
nanosponges loaded with carvacrol. in phosphate buffer saline (150 mM).  (c) Chemical 
structures of PONI-GMT and (d) DTDS. (e) Confocal micrograph of crosslinked micron-
sized biodegradable composites. PONI-GMT labeled with TAMRA-X (red fluorescence), 
and the oil core is loaded with DiO (green fluorescence). A composite morphology is 
indicated by co-distribution of PONI-GMT with the hydrophobic oil core. Scale bar is 
3µm. 
 
4.2. Results 
4.2.1 Generation and Characterization of Nanocomposites 
The X-BNC platform uses a poly(oxanorborneneimide) scaffold bearing guanidine, 
maleimide, and tetraethyleneglycol monomethyl ether groups (PONI-GMT) and provides 
a well-controlled and scalable platform. Biodegradability was imparted through use of a 
dithiol-disulfide (DTDS) crosslinker that is stable > 2 years in storage (Supporting Figure 
4.7). An additional degradation modality was provided using ester-linked maleimide 
groups to enable thiols of DTDS to crosslink rapidly once the polymers assemble at the 
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oil-water interface.37 Copolymerization of monomers bearing guanidine, maleimido, and 
tetreaethylene glycol monomethyl ether units at a 40:10:50 monomer ratio respectively 
provided the precursor polymer PONI-GMT.  The maleimido monomer ratio was kept 
low to ensure adequate solubility of PONI-GMT in aqueous conditions, necessary for 
efficient nanocomposite formation. 
Nanocomposites were fabricated by emulsifying carvacrol oil loaded with DTDS 
or carvacrol only (non-crosslinked control, NX-NC) into water. Upon emulsification, 
PONI-GMT assembles and initially stabilizes the oil-water interface. In the presence of 
DTDS, crosslinking further stabilizing the oil droplets in water. PONI-GMT and DTDS 
generated nanocomposites (X-BNCs) with a diameter of ~220nm as shown by dynamic 
light scattering (DLS). We hypothesized the overall charge of X-BNCs would be reversed 
yielding a positively charged surface. The measured zeta (ζ) potential (Supporting Figure 
4.8) supported this prediction, reporting a cationic nanocomposite, attributed to guanidine 
units at or beyond the oil-water interface. Significantly, DLS experiments on stock 
solutions of X-BNCs that were stored on the bench for one year indicated the composites 
maintained stability with a minimal change in size (Supporting Figure 4.9). 
Next, the morphology (core-shell versus nanocomposites) of X-BNCs was 
established through confocal microscopy of larger micron-sized analogs of the X-BNC 
nanoemulsions. TAMRA-X (red fluorescence) was conjugated to PONI-GMT, while 3,3-
dioctadecyloxacarbocyanine (DiO, green fluorescence) was loaded within the oil. As 
shown in Figure 4.1e, both green and red fluorescence were co-distributed across the 
microparticle, indicating the morphology adopts a composite “sponge” architecture. Given 
that previous reports have observed norbornene-based polymers (Mn’s ~ 100,000 g/mol) 
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adopt length scales of ~ 40 nanometers,38 it is reasonable to suggest that PONI-GMT 
would exist in a composite morphology in the X-BNCs nanoemulsions. This notion is 
further supported in literature as carvacrol and other phytochemicals are miscible with 
glycols,39 such as the high density of tetraethylene glycol units found on PONI-GMT. 
4.2.2 Stability and Degradability of X-BNCs 
Macromolecular vehicles need to be stable to deliver therapeutic payloads yet 
degrade to avoid vehicle accumulation over time.40 After characterizing the morphology of 
X-BNCs, we next probed the colloidal stability of the composites via monitoring particle 
size by dynamic light scattering (DLS).41 As shown in Figure 4.2a, when X-BNCs were 
incubated with 10% serum media for 2 hours, an increase in X-BNCs size (~25 nm) was 
observed, suggesting negatively charged serum proteins adsorb onto the positively charged 
X-BNCs surface. Notably, no evidence of X-BNC destabilization/aggregation was 
observed even at longer incubation times (e.g. 6 hours). However, as a control, non-
crosslinked analogues using the same formulation minus DTDS showed essentially no 
stability in serum (Supporting Figure 4.10).  
We next explored the degradability of X-BNCs in the presence of glutathione 
(GSH) and the ester-hydrolyzing enzyme porcine liver esterase (PLE). Using 
physiologically relevant concentrations of both biomolecules, X-BNCs were incubated for 
24 hours with either 10mM GSH or 35 µM PLE (1 U/µL) with PBS as a control. Figure 
4.2b shows the size of X-BNCs remained the same after 24 hours in PBS, however the size 
increased significantly in GSH/PLE solutions, indicating degradation of the 
nanocomposites structure with concomitant generation of agglomerated structures through 
an Ostwald ripening-like process. Taken together, the results indicate the crosslinked 
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composite framework within X-BNCs are robust in serum yet biodegrade in the presence 
of chosen biological environments.  
 
Figure 4.2. Stability and degradability of X-BNCs. DLS size distribution changes of X-
BNCs when incubated with (a) 10% FBS media for two hours or (b) physiologically 
relevant biomolecules (glutathione and lipase) in PBS, showing degradation from disulfide 
cleavage and hydrolysis. 
 
4.2.3 Antimicrobial Activity of X-BNCs Against Biofilms 
We focused our antimicrobial efforts on highly refractory biofilms, where the 
efficacy of traditional antibiotic therapy is significantly compromised relative to planktonic 
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pathogens.42 We investigated the ability of X-BNCs to penetrate EPS followed by 
quantitative analysis of their therapeutic efficacy towards enclosed pathogenic bacteria. X-
BNC penetration into biofilms formed by red fluorescent protein (RFP)-expressing E. coli 
was tracked by loading 3,3-dioctadecyloxacarbocyanine (DiO, green fluorescence) within 
the oil core. As shown in Figure 4.3, X-BNCs readily penetrate and diffuse throughout the 
biofilm, with fluorescence colocalizing with enclosed bacteria. The data demonstrates X-
BNCs deliver their payload efficiently, reaching enclosed pathogens deep within the films 
matrix. 
 
Figure 4.3. Confocal image stacks and penetration profile of E. coli DH5α biofilm after 1-
hour treatment with X-BNCs loaded with DiO. Scale bars are 40µm and are not 
representative of the biofilm depth. Each projected z-stack image (a) is spaced by 1.3 µm 
at a 5o angle from the biofilms x-plane. Both the overlay and biofilm depth fluorescence 
graph (b) indicates X-BNCs completely penetrates the biofilm, colocalizing with bacteria 
that expresses red fluorescent protein. 
 
Next, the antimicrobial activity of X-BNCs against multiple pathogenic Gram-
negative and Gram-positive biofilms were evaluated. Four pathogenic bacterial strains of 
clinical isolates, Staphylococcus aureus (CD-489, a methicillin-resistant strain), 
Pseudomonas aeruginosa (CD-1006), Escherichia coli (CD-2), and Enterobacter cloacae 
(E. cloacae, CD-1412) complex were chosen to be tested as their associated infections are 
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typically common in hospital-related settings.43,44 As shown in Figure 4.4, X-BNCs 
effectively eliminated bacterial cells in all four-biofilm species within 3 hours. Notably, 
both Gram positive (S. aureus) and Gram negative (P. aeruginosa, E. coli, and E. cloacae 
complex) bacteria can be treated with X-BNCs, highlighting their broad-spectrum activity 
even in a biofilm matrix setting. 
 
Figure 4.4. Viability of one-day-old Gram-negative/positive biofilms after a three-hour 
treatment with X-BNCs. The individual components are controls at different emulsion 
concentrations (Displayed as mM and v/v % of emulsion). The results shown are averaged 
triplicates, and the error bars indicate the standard deviation. 
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4.2.4 Selective Killing of Biofilms in a Coculture Model 
Beyond treating biofilms on surfaces, eliminating these bacterial infections on 
human tissue and organs is a greater challenge and more relevant to patients who suffer 
from skin ulcers, burn injuries, or wound trauma. A fundamental issue associated with 
these infections is their ability to interfere with the host’s tissue regeneration process. We 
evaluated the efficacy of X-BNCs as a topical treatment by using an in vitro co-culture 
model comprised of a biofilm grown on top of mammalian fibroblasts. P. aeruginosa and 
NIH 3T3 fibroblast cells were selected to build this co-culture model, since P. aeruginosa 
is widely associated with skin infections and fibroblast cells are critical during wound 
healing.45,46,47 The co-cultures were treated with X-BNCs for 3 hours, washed, and the 
viabilities of bacteria and fibroblast cells were determined. As shown in Figure 4.5, a 4-
fold log reduction (~99.5%) in biofilm colonies was observed at a X-BNCs concentration 
of 16 v/v %., while 3T3 fibroblast viability remained uncompromised. Significantly, little 
change in fibroblast viability was observed at 32 v/v %, where a 6-log unit reduction in 
bacteria was observed. This selective toxicity to biofilm bacteria makes the X-BNC 
platform promising for addressing wound biofilms. 
92 
 
 
Figure 4.5. Viability of 3T3 fibroblast cells and P. aeruginosa biofilms in the coculture 
model after treating X-BNCs at different emulsion concentrations for three hours. 3T3 
fibroblast cell viabilities are shown as a line. Bar plots represent log10 of colony-forming 
bacteria units in biofilms. Each result is an average of three experiments, and the error bars 
designate the standard deviations. 
 
4.2.5 Bacterial Resistance Towards Antibiotics Vs. X-BNCs 
The number of antibiotic-resistant bacteria and their associated infections is 
increasing globally, leading to cases where infections have become untreatable. Although 
efforts to discover novel antibiotic classes to slow the progression of antibiotic resistance 
is ongoing,48 developing alternative therapeutic platforms where bacteria cannot develop 
resistance towards must take precedence. We hypothesized that the membrane disruption 
induced by the antimicrobial phytochemical payload of X-BNCs would sidestep normal 
bacterial defense adaptations, preventing accumulated resistance. We tested this hypothesis 
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by subjecting planktonic bacteria to X-BNCs and a negative control antibiotic 
(ciprofloxacin, enzyme inhibitor) in the presence of propidium iodide (PI, Supporting 
Figure 4.11). PI is not permeant to live bacterial cells, however easily diffuses through 
membrane-compromised cells, generating fluorescence upon intercalating with DNA. X-
BNC treatment quickly generated PI fluorescence, indicating their action mechanism 
compromises bacterial membrane integrity. Ciprofloxacin is an enzyme inhibitor antibiotic 
and therefore does not act on bacterial membranes, generating no observed fluorescence. 
Next, pathogenic E. coli (CD-2) was passaged in the presence of X-BNCs, or three 
commercially available antibiotics, ciprofloxacin (quinolone class), ceftazidime (β-lactam 
class), and tetracycline (tetracycline class). Briefly, we subjected the bacteria to the sub-
minimum inhibitory concentrations (66% of MIC) of the antimicrobial agent.  The resulting 
bacterial populations for each individual therapeutic was defined as the first passage, 
harvested, and their respective MICs evaluated. The subsequent passage was derived by 
exposing the previous passage with the 66% MIC of each respective therapeutic dosage. 
As shown in Figure 4.6a, no resistance was generated towards X-BNCs even after 20 serial 
passages (~1,300 bacterial generations). Meanwhile, E. coli rapidly developed resistance 
towards each of the antibiotics, with respective MIC increases of 33,000, 4,200, and 256-
fold where the drugs reached their solubility limit in media. Going further, biofilms were 
grown with the 20th serial passage and subjected to X-BNCs for 3 hours, where CD-2 E. 
coli was still susceptible to nanoemulsion treatment (Figure 4.6b). These results indicate 
the mechanism of X-BNCs mitigates the onset of resistance in both planktonic and biofilm 
settings.  
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Figure 4.6. Accumulated resistance of pathogenic E. coli (CD-2) in both plankton and 
biofilm settings. (a) Resistance development of planktonic species during serial passaging 
in the presence of sub-MIC dosing’s of antimicrobials. The y-axis indicates the increase in 
dosage as compared to the initial bacterial cells (0th passage) and the figure is 
representative of three independent experiments. (b) Derived E. coli cells from 20 serial 
passages of sub-MIC X-BNCs dosing was grown into a biofilm and subjected to a three-
hour treatment of X-BNCs at different emulsion concentrations. The results indicate that 
evolved pathogenic E. coli remain susceptible to X-BNCs. 
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4.3. Conclusions 
In summary, we report the construction, characterization, and antimicrobial 
potential of a biodegradable crosslinked polymer-stabilized oil-in-water nanocomposite. 
These nanoemulsions maintain stability in serum yet degrade in the presence of selected 
biomolecules, a necessary attribute to avoid vehicle accumulation over time. Furthermore, 
the nanocomposites are highly effective against both Gram negative and positive bacteria 
biofilms, with no observed toxicity to mammalian fibroblast cells. In stark contrast to 
traditional antibiotics, bacteria were unable to accumulate resistance towards our 
nanoemulsions whether the bacteria were planktonic or in biofilms.  The therapeutic 
polymer-based phytochemical nanoemulsion we present is a highly promising 
antimicrobial platform with the potential to impact treatment of wound biofilms and other 
difficult bacterial infections. 
 
4.4. Experimental Protocols 
4.4.1 Materials and Methods 
All reagents and materials were purchased from Fisher Scientific and used as 
received. NIH-3T3 cells (ATCC CRL-1658) were purchased from ATCC. Dulbecco’s 
Modified Eagle’s Medium (DMEM) (DMEM; ATCC 30-2002) and fetal bovine serum 
(Fisher Scientific, SH3007103) were used in cell culture. Pierce LDH Cytotoxicity Assay 
Kit was purchased from Fisher Scientific. 
4.4.2 Preparation of Nanocomposites 
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Stock nanocomposite solutions were prepared in 0.6 ml Eppendorf tubes. To 
prepare the stock X-BNC emulsions, 3 µL of carvacrol oil (containing 3 wt% DTDS) was 
added to 497 µL of Milli-Q H2O containing 6 µM of PONI-GMT and emulsified in an 
amalgamator for 50 s. The non-crosslinked analogs were done in the same fashion however 
without DTDS dissolved in carvacrol. The emulsions were allowed to rest overnight prior 
to use. 
4.4.3 Biofilm Formation 
Bacteria were inoculated in LB broth at 37°C until stationary phase. The cultures 
were then harvested by centrifugation and washed with 0.85% sodium chloride solution 
three times. Concentrations of resuspended bacterial solution were determined by optical 
density measured at 600 nm. Seeding solutions were then made in M9 to reach OD600 of 
0.1. 100 μL of the seeding solutions were added to each well of the microplate. M9 medium 
without bacteria was used as a negative control. The plates were covered and incubated at 
room temperature under static conditions for a desired period. Planktonic bacteria were 
removed by washing with PB saline three times.  
Varied v/v % of X-NCs, made in M9 medium, were incubated with the biofilms for 3 
h. Biofilms were washed with phosphate buffer saline (PBS) three times and viability was 
determined using an Alamar Blue assay. M9 medium without bacteria was used as a 
negative control. 
4.4.4 Biofilm – 3T3 Fibroblast Cell Co-culture 
A total of 20,000 NIH 3T3 (ATCC CRL-1658) cells were cultured in Dulbecco's 
modified Eagle medium (DMEM; ATCC 30-2002) with 10% bovine calf serum and 1% 
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antibiotics at 37oC in a humidified atmosphere of 5% CO2. Cells were kept for 24 hours to 
reach a confluent monolayer. Bacteria (P. aeruginosa) were inoculated and harvested. 
Afterwards, seeding solutions were made in buffered DMEM supplemented with glucose 
to reach an OD600 of 0.1. Old medium was removed from 3T3 cells followed by addition 
of 100 μL of seeding solution. The co-cultures were then stored in a box with damp paper 
towels at 37oC overnight without shaking. Testing solutions at different concentrations 
were made by diluting nanocomposites into DMEM prior to use.  Media was removed from 
co-culture, replaced with testing solutions, and incubated for 3 hours at 37oC. Co-cultures 
were then analyzed using a LDH cytotoxicity assay to determine mammalian cell viability.  
To determine the bacteria viability in biofilms, the testing solutions were removed, and co-
cultures were washed with PBS. Fresh PBS was then added to disperse remaining bacteria 
from biofilms in co-culture by sonication for 20 min and mixing with pipet. The solutions 
containing dispersed bacteria were then plated onto agar plates and colony forming units 
were counted after incubation at 37oC overnight. 
4.4.5 Membrane Disruption Study via PI Staining 
P. aeruginosa was cultured in LB medium at 37oC and 275 rpm until reaching the 
stationary phase. The cultures were centrifuged then resuspended in 70% isopropyl alcohol 
for obtaining dead bacteria or resuspended in 0.85% sodium chloride solution for live 
bacteria. Both bacteria were incubated for 1 hour at room temperature and then washed 
with 0.85% sodium chloride solution again. The O.D. of these solutions were determined 
and adjusted to 1. 
100 μL of live bacteria were added to the wells of a black 96-well plate. 5 uL of 1 
mg/L propidium iodide (PI) was then added. Fluorescence intensities were measured 
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immediately after adding 100 μL of PBS containing 10X MIC of X-BNCs 
(Excitation/Emission: 535 nm/ 617 nm). Live bacteria were also treated with PI and 
ciprofloxacin as negative control. Dead bacteria were treated with PI as positive control. 
4.4.6 Synthesis of DTDS (3) 
SH + Br OH
O
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HS O
O
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3  
Synthesis of 1. To a 250ml round bottom flask equipped with a stir-bar was added 
triphenylmethylmercaptan (5.0g, 18.09mmol, 1.0eq), 11-bromoundecanoic acid (4.80g, 
18.09mmol, 1.0eq), and 75ml of both toluene and ethanol. The mixture was allowed to stir 
to completely dissolve the reagents. Meanwhile, sodium hydroxide (1.60g, 39.80mmol, 2.2 
eq) was dissolved in a minimal amount of water and then added to the reaction flask. The 
flask was heated to 80oC for 4 hours, cooled to room temperature, and the solvents 
rotovaped. Water was then added, and the mixture acidified with 1M HCL. The aqueous 
mixture was extracted with ethyl acetate three times. The combined organic layers were 
washed with brine, dried with sodium sulfate, filtered, and rotovaped to yield an off-white 
solid that was purified through column chromatography to yield 1 (White solid, yield = 
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92%). (1H NMR, CDCL3, 400 MHz) 11.2 (br, 1H), 7.45 (d, 6H), 7.3 (t, 6H), 7.21 (t, 3H), 
2.35 (t, 2H), 2.15 (t, 2H), 1.65 (m, 2H), 1.4 (m, 2H), 1.25 (m, 12H). 
 
Synthesis of 2. To a 250ml round bottom flask equipped with a stir-bar was added 1 (4.71g, 
10.22mmol, 2.0eq), 2-hydroxyethyl disulfide (0.63ml, 5.11mmol, 1.0eq), 4-
dimethylaminopyridine (0.31g, 2.55mmol, 0.5eq), and 100ml of dichloromethane. The 
reaction flask was stirred and finally N,N’-dicyclohexylcarbodiimide (2.22g, 10.74mmol, 
2.1eq) was added and allowed to stir at room temperature overnight. Afterwards, the 
solvent was evaporated and diethyl ether (150ml) was added to the reaction residue, 
sonicated, and placed in a freezer for 1 hour to precipitate most of the DCU biproduct. The 
reaction mixture was filtered and washed with cold diethyl ether. The filtrate was rotovaped 
and the product was purified with column chromatography to yield 2 (light yellow, yield = 
90%). (1H NMR, CDCL3, 400 Mhz) 7.41 (d, 12H), 7.28 (t, 12H), 7.21 (t, 6H), 4.35 (t, 4H), 
2.92 (t, 4H), 2.32 (t, 4H), 2.15 (t, 4H), 1.63 (m, 4H), 1.4 (m, 4H), 1.25 (m, 24). 
 
Synthesis of 3 (DTDS). To a 250ml round bottom flask equipped with a stir-bar, was added 
2 (2.6g, 2.50mmol, 1.0eq). Next, nitrogen was bubbled through 100ml of dichloromethane 
for 5 minutes and added to the reaction flask. The flask was sealed with a septum and a 
continuous flow of nitrogen was introduce to the reaction flask until after trifluoroacetic 
acid (7.66ml, 100.04mmol, 40.0eq) was added. The reaction mixture color immediately 
changed to yellow and was allowed to stir for 30 minutes to completely form the 
triphenylmethyl carbocation. After 30 minutes, triisopropylsilane (1.1ml, 5.25mmol, 
2.1eq) was added to the reaction flask and allowed to stir for 1 hour. During this time the 
color changed back to nearly colorless. Afterwards, excess trifluoroacetic acid was 
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removed by rotovaping the reaction 4 times with 100ml of dichloromethane. The obtained 
residue was easily purified and isolated using column chromatography with no degradation 
or rearrangement of 3 (DTDS, off-white solid, yield = 85%). (1H NMR, CDCL3, 400 MHz) 
4.31 (t, 4H), 2.91 (t, 4H), 2.5 (q, 4H), 2.31 (t, 4H), 1.61 (m, 8H), 1.31 (m, 24H). 
 
4.4.7 Synthesis of PONI-GMT 
Maleimide Monomer Synthesis (8) 
Note: Synthesis of ONI-H, 9, and 10 has been reported previously.30
O + O OO Et2O
r.t. overnight
O
OO O
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OH
O
O
O
OH
O
5
O
N
H
O
O
+
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Cl OH
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DMF, 50oC
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O N
O
O OH
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O
OH
O
5
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O
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O
O
O
O
O
N
O
O
8  
Synthesis of 4. To a 250ml round bottom flask equipped with a stir-bar, was added furan 
(18.5ml, 255.0mmol, 5.0eq) and 100ml of diethyl ether. Maleic anhydride (5.0g, 
51.0mmol, 1.0eq) was added to the flask and the reaction was stirred at room temperature 
overnight. Afterwards, the formed precipitate in the reaction flask was filtered and washed 
with copious amounts of diethyl ether to afford 4 (white solid, yield = 88%). (1H NMR, 
DMSO-D6, 400 MHz) 6.55 (s, 2H), 5.31 (s, 2H), 3.3 (s, 2H). 
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Synthesis of 5. To a 250ml round bottom flask equipped with a stir-bar, was added 4 (7.5g, 
45.22mmol, 1.0eq), 4-dimethylaminopyridine (0.55g, 4.52mmol, 0.1eq), and 100ml of 
dichloromethane. Anhydrous ethanol (3.17ml, 54.26mmol, 1.2eq) was added and the 
reaction was stirred at room temperature overnight. Afterwards the solvent was evaporated, 
and the product was purified with column chromatography to yield 5 (White solid, yield = 
82%). (1H NMR, CDCL3, 400 MHz) 10.2 (br, 1H), 6.45 (q, 2H), 5.28 (s, 1H), 5.21 (s, 1H), 
4.15 (q, 2H), 2.81 (q, 2H), 1.21 (t, 3H). 
Synthesis of 6. To a 250ml round bottom flask equipped with a stir-bar, was added ONI-
H (7.0g, 42.40mmol, 1.0eq) and 50ml of n,n-dimethylformamide. Then, potassium 
carbonate (23.40g, 169.55mmol, 4.0eq) was added and the reaction flask was stirred at 
50oC for 5 minutes. Afterwards, sodium iodide (1.27g, 8.48mmol, 0.2eq) was added 
followed by 3-chloropropanol (3.72ml, 44.51mmol, 1.05eq) and the reaction flask was 
stirred overnight at 50oC. Afterwards, the reaction flask was cooled to room temperature 
and water was added. The reaction mixture was transferred to a separatory funnel and 
extracted with ethyl acetate three times. The organic layers were combined and washed 
with saturated sodium bicarbonate, 1M HCL, and brine. The organic layer was dried with 
sodium sulfate, filtered and rotovaped to yield a solid residue that was purified using 
column chromatography to afford 6 (White solid, yield = 86%). (1H NMR, CDCL3, 400 
MHz) 6.49 (s, 2H), 5.21 (s, 2H), 3.58 (t, 2H), 3.49 (q, 2H), 2.81 (s, 2H), 2.65 (br, 1H), 1.73 
(m, 2H). 
Synthesis of 7. To a 250ml round bottom flask equipped with a stir-bar, was added 6 (7.0g, 
31.36mmol, 1.0eq) and 150ml of toluene. A dean-stark trap was added to the reaction flask 
and the reaction was stirred under reflux overnight. Afterwards, the solvent was rotovaped 
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and purified using column chromatography to afford 7 (White solid, yield = 88%). (1H 
NMR, CDCL3, 400 MHz) 6.65 (s, 2H), 3.6 (t, 2H), 3.51 (t, 2H), 2.65 (br, 1H), 1.73 (m, 
2H). 
Synthesis of 8. To a 250ml round bottom flask equipped with a stir-bar, was added 7 (1.6g, 
10.31mmol, 1.0eq), 5 (2.20g, 10.31mmol, 1.0eq), 4-dimethylaminopyridine (0.13g, 
1.03mmol, 0.1eq), and 100ml of dichloromethane. The reaction flask was cooled to 0oC 
and 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (2.17g, 11.34mmol, 1.1eq) was 
added and stirred at 0oC for 10 minutes, followed by at room temperature for 2 hours. 
*Note: It is critical to only allow the reaction to proceed for 2 hours and not overnight. 
Leaving the reaction overnight will result in complete degradation of the product.* 
Afterwards, the solvent was rotovaped and the residue was purified using column 
chromatography to afford 8 (Light yellow oil, yield = 75%). (1H NMR, CDCL3, 400 MHz) 
6.69 (s, 2H), 6.45 (s, 2H), 5.29 (s, 1H), 5.23 (s, 1H), 4.13 (t, 2h), 4.1 (m, 2H), 3.61 (t, 2H), 
2.8 (s, 2H), 1.92 (m, 2H), 1.25 (t, 3H). 
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Synthesis of Polymer 11. To a 10ml pear-shaped air-free flask equipped with a stir-bar 
was added 9 (0.27g, 0.57mmol, 0.4eq), 10 (0.25g, 0.72mmol, 0.5eq), 8 (0.05g, 0.14mmol, 
0.1eq), and 4ml of dichloromethane.  In a separate 10ml pear-shaped air-free flask was 
added Grubbs 3rd generation catalyst (0.015g, 0.017mmol, 0.012eq) and 1ml of 
dichloromethane.  Both flasks were sealed with septa and attached to a schlenk 
nitrogen/vaccum line.  Both flasks were freeze-pump-thawed three times.  After thawing, 
Grubbs 3rd generation catalyst solution was syringed out and quickly added to the flask 
containing the monomers and allowed to react for 12 minutes. After the allotted time, ethyl 
vinyl ether (200 µL) was added and allowed to stir for 15 minutes.  The reaction mixture 
was then diluted to two times the volume and precipitated into a heavily stirred solution of 
ether:hexane (150ml, 1:1 volume ratio) to yield Polymer 11. MW = 46,157, PDI = 1.45, as 
determined by THF GPC using a polystyrene calibration curve). 1H NMR (500MHz, 
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CDCl3) 11.49 (s, 2H), 8.45 (br, 2H), 6.71 (br, 0.8H), 6.09 (br, 4H), 5.8 (br, 6H), 5.05 (br, 
6H), 4.5 (br, 4H), 3.65 (br, 52H), 3.45 (br, 2H), 3.35 (s, 7H), 3.33 (br, 2H), 1.89 (br, 4H), 
1.8 (br, 4H), 1.49 (s, 20H), 1.2 (br, 2H). 
 
Synthesis of Polymer 12. To a 50ml round bottom flask equipped with a stir-bar was added 
Polymer 11 (400 milligrams).  Dichloromethane was purged with nitrogen for five minutes 
and 12ml was added to the flask, sealed with a septum and purged with nitrogen for five 
minutes.  The main nitrogen line was left in the septum and the nitrogen pressure was 
reduced to a steady stream. 12ml of trifluoroacetic acid (excess) was added and the reaction 
was stirred for two hours.  Afterwards, excess TFA was removed by rotovaping with 
dichloromethane, three times. The reaction residue was dissolved in a minimal amount of 
water, filtered through a polyethersulfone (PES) syringe filter and lyophilized to yield 
polymer 12 as a white solid which readily dissolves in water. MW ~ 33,157, as determined 
using GPC. 1H NMR (400MHz, D2O) 6.7 (br, 0.4H), 5.94 (br, 4H), 5.74 (br, 4H), 4.82 (br, 
4H), 4.45 (br, 4H), 3.5 (br, 40H), 3.2 (s, 6H), 3.02 (br, 4H), 1.7 (br, 4H), 1.05 (br, 2H). 
Synthesis of TAMRA-PONI-GMT 
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4.4.8 Synthesis of TAMRA-PONI-GMT 
To a 7ml scintillation vial equipped with a stir-bar, was added 5(6)-TAMRA-X, SE 
(0.001g, 0.0016mmol, 1.0eq), pyridine (0.14ml, 0.0017mmol, 1.1eq), and 1ml of 
anhydrous DMSO (previously purged with nitrogen). A blanket of nitrogen was introduced 
to the vial, cysteamine (0.00012g, 0.0016mmol, 1.0eq) was added, the vial was sealed, 
covered with aluminum foil, and was stirred at room temperature for 3 hours. Meanwhile, 
in a 20ml scintillation vial equipped with a stir-bar, was added Polymer 12 (0.08g), N,N-
diisopropylethylamine (0.1ml), and 2ml of anhydrous DMSO. After three hours, the 
terminal thiol-TAMRA that was generated in situ was added to the stirred vial containing 
Polymer 12, covered with aluminum foil, sealed with a blanket of nitrogen, and stirred at 
room temperature overnight. Afterwards, the reaction vial was diluted with water and 
acidified using 1M HCL as to avoid a turbid solution. The reaction solution was completely 
homogenous at this time and was transferred to a 10,000 MWCO dialysis snake skin 
tubing. The dialysis tube was stirred in a 5L bucket for three days, changing the water every 
two hours the first day, and periodically for the remaining two days. Afterwards, the 
reaction solution was filtered through a PES syringe filter and lyophilized to afford 
TAMRA-PONI-GMT (Red-crystalline solid). TLC analysis (Mobile phase = ethyl 
acetate) of TAMRA-PONI-GMT against the in situ generated terminal thiol indicated that 
TAMRA was successfully conjugated to 12 in addition to any free TAMRA dye being 
removed during dialysis. 
 
4.5. Supporting Figures 
106 
 
4.5.1 DTDS Storage Stability 
 
 
Figure 4.7. Storage of DTDS. DTDS was stored in a nitrogen purged 20ml scintillation 
vial, covered with aluminum foil and kept in a -4oC freezer for over two years. 1H NMR 
analysis of DTDS two years later revealed no degradation or rearrangement of its initial 
structure. It is hypothesized that DTDSs stability is attributed to its solid physical 
properties. 
 
4.5.2 Zeta Potential of X-BNCs 
 
Figure 4.8. Zeta potential of X-BNCs. The cationic charge is derived from guanidine 
moieties found on PONI-GMT and is expected to be located at the oil-water interface and 
throughout the emulsion, given the architecture is a composite morphology. 
 
4.5.3 Long-Term Storage of X-BNCs 
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Figure 4.9. Size distribution of X-BNCs stock solution in PBS after 1 year of storage. The 
average size of X-BNCs increased to ~ 310nm indicating that the crosslinking scaffold of 
X-BNCs slows the onset of flocculation. 
 
4.5.4 Serum Stability of NX-NCs 
 
Figure 4.10. DLS size distribution. Size distribution of non-crosslinked analogs of X-
BNCs (NX-NCs) after two hours in 10% fetal bovine serum using dynamic light scattering 
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(DLS) measurements. NX-NCs show no stability in serum-containing conditions with the 
DLS results indicating only serum proteins present. 
 
 
Figure 4.11. Percentage of P. aeruginosa stained by propidium iodide (PI) following 
treatment with X-BNCs or ciprofloxacin. X-BNCs quickly disrupted cell membrane, 
therefore PI could bind to nucleic acids and generate red fluorescence. However, no 
fluorescence was observed with ciprofloxacin as its action mechanism towards bacteria 
involves enzyme inhibition and not membrane disruption. The remaining percent of P. 
aeruginosa that were not stained is likely due to the large concentration of bacteria used 
(OD = 0.5) along with a complete consumption of X-BNC composites during the study. 
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CHAPTER 5 
NATURE-DERIVED CROSSLINKED NANOCOMPOSITES 
FOR A SUSTAINABLY-RELAVENT TREATMENT OF 
MULTIDRUG-RESISTANT BIOFILMS 
 
 
5.1. Introduction 
Overuse of antibiotic regimens in biomedical and agriculture industries has directly 
contributed to the exponential growth of multidrug-resistant (MDR) pathogenic bacteria 
and their associated infections found in hospitals or on farms.1 Current death toll 
predictions indicate that by 2050, 10 million lives will be lost each year, along with 
incurring costs exceeding $100 trillion.2 This issue is only further exacerbated by serious 
chronic infections caused by bacterial biofilms, nearly untreatable by long-term antibiotic 
therapies coupled with dead tissue debridement tactics.3 As the clinical antibiotic pipelines 
continue to ‘dry-up’, an international push to discover sustainable methods to combat MDR 
infections has taken priority.4 
A variety of antibiotic alternatives have emerged or are being reinvestigated for 
their therapeutic relevance towards MDR. Notably, host-guest peptides,5 bacteriophages,6 
and antibodies7 are three main therapeutic avenues that have shown promise either in vitro 
or in a clinical setting. These methods offer key advantages over antibiotic counterparts, 
including mammalian toxicity reduction,8 high specificity,9 and can be potentially 
administered where accumulated resistance is less likely to happen.10 Furthermore, host-
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guest peptides and antibodies are already in clinical trials and have shown good promise, 
delivering the possibility of antibiotic alternatives for upcoming decades.11 However, the 
benefits of these therapeutic methods are still out-weighted by their drawbacks. In the case 
of host-guest peptides, the adverse effects of red blood cell lysis (hemolysis) remain with 
almost all peptide analogs.12 Regarding bacteriophages, disease models in animals and 
humans are low compared to the other two methods and more experimental insight is 
required to better understand their mechanism and long-term effects.13 While antibodies 
offer a low toxicity avenue, their effectiveness has been better demonstrated in high-risk 
patients and has had less success as a therapeutic intervention.14 Finally, all three of these 
methods suffer from poor scale-up logistics, a process most critical if global adoption is to 
be considered. It is clear that whichever strategy is chosen to replace antibiotics, their 
ability to be produced and administered must be sustainable and environmentally 
conscience.  
Another promising alternative that has emerged in recent decades is the 
encapsulation of essential oils in nano-carrier delivery vehicles.15 Essential oils offer high 
biocompatibility,16 significantly lower cost than other antimicrobials, and has been 
demonstrated in vitro to eliminate MDR pathogens, even in a biofilm setting or coculture 
wound models.17 Furthermore, a variety of crosslinkable nano-carriers have been 
developed to stabilize essential oils in water, dramatically enhancing their bioactive 
properties and stability.18 Although great efforts have been made to translate these research 
materials into commercially viable products, the carrier’s stabilizers are made from 
poly(oxanorbornene) synthetic polymers using ‘heavy-metal’ ruthenium catalysts. 
Residual ruthenium leftover from polymerization may raise concerns about their long-term 
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genotoxicity to mammalian hosts.19 Therefore, if low-cost natural stabilizers could be bio-
compatibly crosslinked at an essential oil-water interface, in theory, highly robust and 
sustainable essential oil carriers could be developed to address the rising dangers of MDR 
on a global scale consideration. 
Inspired by a recently developed Corneal Collagen Crosslinking (CXL)20 technique 
using riboflavin and UV-A light, we hypothesized that hydrolyzed collagen fragments 
(Gelatin) could also be intermolecularly crosslinked in a similar fashion demonstrated in 
CXL, but at an oil-water interface. Herein, we report the generation, characterization, and 
biological activities of crosslinked gelatin-stabilized nanocomposites containing the highly 
antimicrobial oil carvacrol (GEL-XC). We demonstrate though dynamic light scattering 
(DLS), GEL-XCs could retain an average size of 300 nm regardless of their production on 
a microliter or liter-scale, with slight modifications to the emulsification procedure. 
Additionally, GEL-XCs were shown to adopt a composite morphology under confocal 
microscopy and retained their size and stability during a two-year shelf-life test. 
Furthermore, GEL-XCs were as equally capable of eliminating Gram-Negative and Gram-
Positive MDR pathogens, even in a biofilm setting when compared to previous synthetic 
essential oil composites. Finally, future work continues to determine GEL-XCs 
effectiveness in vivo as a wound healing agent in mice and will be reported in due course. 
Taken together, the bio-inspired oil-in-water crosslinking presented here may address the 
needs for a sustainably-relevant antibiotic alternative with hopes future platforms will be 
further developed around this crosslinking strategy with applications in biomedical, 
agriculture, food, surface, and textile industries. 
5.2. Results 
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5.2.1 Generation of GEL-XCs 
Generation of gelatin-stabilized nanocomposites was accomplished through 
emulsifying carvacrol oil containing partially dissolved and suspended riboflavin and an 
aqueous solution containing 3 mg/ml of gelatin type B (MW ~20,000 g/mol), followed by 
irradiation with 365 nm light (Figure 5.1a). Briefly, 3 µL of carvacrol loaded with 0.1 
wt% of riboflavin was amalgamated for 60 seconds with a 497 µL solution of gelatin type 
B (pre-warmed to 37oC) in a 600 µL Eppendorf tube. Afterwards, Eppendorf tubes 
containing the oil-templated gelatin emulsion was subjected to a handheld 365nm UV 
lamp for 20 minutes. After irradiation, the emulsion solution became more apparently 
viscous and opaque. Notably, emulsion controls including the absence of either gelatin, 
riboflavin, or UV light did not generate stable emulsions and fell apart one day after 
emulsification (in the case of no gelatin present, no emulsion was observed). The size of 
GEL-XCs was characterized through dynamic light scattering (DLS). The DLS results 
obtained showed narrow PDI as gelatin type B’s refractive index is well understood and 
agreeance in Intensity, Number, and Volume size was observed with an average size of 
300 nm (Figure 5.1b). Figure 5.1c shows the proposed mechanism of crosslinking and 
will be discussed later.21 Notably, GEL-XCs demonstrated high shelf-life, maintaining its 
inherent size even after on the benchtop for 2 years. 
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Figure 5.1. a) Schematic depiction of GEL-XCs generation. b) Proposed mechanism of 
inter-gelatin crosslinking mediated by photooxidation. c) Dynamic light Scattering of 
GEL-XCs in 150mM PBS. 
5.2.2 Morphology of GEL-XCs 
After GEL-XCs formulation was optimized, its morphology was observed under 
confocal microscopy by generating micron-sized emulsion analogs. Given that gelatin fits 
similar size domains as compared to previously generated synthetic norbornene polymer 
stabilizers, it is hypothesized that the morphology for micron or nano-sized emulsions 
will be largely the same. First, gelatin was labelled with a blue fluorescent coumarin dye 
through its residual lysine residues that take no part in the crosslinking process. Next, 
green fluorescent DiO dye was loaded within the oil to clearly juxtapose the oil core from 
the gelatin stabilizer. Micron-sized emulsions were viewed under confocal and analyzed 
with Image J software (Figure 5.2). The results indicate that gelatin can be observed to 
co-localized with the oil core in addition to localizing at the oil-water interface and 
beyond. The reason for this observation can be hypothesized as the following. Gelatin’s 
native structure contains a large number of proline and hydroxyproline residues, 
imparting β-sheet structures.22 Additionally, gelatin contains numerous hydrophobic 
residues that carvacrol oil can embed within. Crosslinked gelatin would in theory be a 
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more hydrophobic material given the number of hydrophobic residues outweigh its polar 
residue domains. Explanation of gelatin present beyond the oil can be explained during 
its formulation process. Although riboflavin has some solubility in carvacrol, it is not 
completely soluble. Therefore, during UV irradiation, riboflavin leaks into the water and 
enables crosslinking units beyond the oil. Residual gelatin still floating outside of the 
emulsions may attach later on. This is further supported in the confocal as entire 
emulsions can be crosslinked and are linked through these exterior gelatin appendages. 
No evidence of inter-emulsion crosslinking can be observed under DLS when nano-sized 
emulsions are formed, suggesting that this type of crosslinking occurs during 
emulsification of a larger volume oil. Taken together, GEL-XCs largely adopt a 
composite morphology with hydrogel-like appendages, a particularly interesting result. 
Future studies to generate additional nano and micron-sized structures are underway. 
 
 
Figure 5.2. a) Confocal of isolated GEL-XCs emulsion indicating a composite 
morphology, in addition to hydrogel-like appendages found external to the oil-water 
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interface. b) Confocal z-stack images at a 15o from x-axis vector demonstrating inter-Gel-
XC crosslinking via hydrogel-like appendages. Scale bars are 2 and 20 µm, respectively. 
5.2.3 Chemical Identification of GEL-XCs 
After characterization of GEL-XCs physical and morphological attributes, its 
chemical properties were explored, particularly its crosslinking mechanism route. As 
shown in Figure 5.1, prior literature indicates that UVA irradiation of riboflavin generates 
singlet oxygen, oxidizing imidazole units on histidine residues on collagen (Or in this 
case, gelatin) to imidazolones.23 Imidazolones are susceptible to nucleophilic attack from 
hydroxy moieties found within gelatin (e,g, hydroxyproline, tyrosine, and serine). We 
hypothesize that gelatin’s crosslinking occurs through this mechanism with an additional 
step. Given the relatively high concentration of carvacrol at the sites of crosslinking, its 
phenol unit may also participate in the reaction in a similar fashion as gelatin’s tyrosine 
residues. Furthermore, this result would give additional support to GEL-XCs morphology 
as conjugated carvacrol onto gelatin would impart further hydrophobic domains and 
interact more with the oil core. We used attenuated total reflectance Fourier transform 
infrared spectroscopy to monitor both inter-gelatin crosslinking and carvacrol-gelatin 
conjugation (Figure 5.3). Figure 5.3a shows the ATR spectra for carvacrol with its 
indicative peaks, including a phenol stretch at 3337 cm-1, aliphatic C-H stretches at 2959, 
2927, and 2860 cm-1, alkane bending at 1457 and 1419 cm-1, and C-O stretch at 1250 cm-
1. Next, three individual reactions were setup to monitor changes in gelatin’s IR 
frequencies. The first reaction (Figure 5.3b, positive control) mixes riboflavin and gelatin 
in the presence of UVA light for 30 minutes, the second (Figure 5.3c, negative control) 
performs the same reaction however in the presence of sodium azide, a well-known 
quencher of singlet oxygen. The final experiment (Figure 5.3d) is generation of GEL-
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XCs. All three reactions underwent dialysis and were lyophilized to remove by-product 
noise (riboflavin, residual carvacrol oil, sodium azide, and water). The results indicate 
that inter-gelatin crosslinking occurs (aliphatic ether formation: 1118 cm-1, aliphatic-
aromatic ether formation: 1033 cm-1) in the positive control, however these signatures are 
completely absent in the negative control.24 Interestingly, GEL-XCs IR spectra not only 
shows inter-gelatin crosslinking signatures (Stronger in frequency due to gelatin 
concentration at the oil-water interface), but signatures from gelatin-carvacrol 
conjugation can also be seen (broadening of 1033 cm-1 and additional aromatic ether 
signature at 1242 cm-1). Furthermore, obvious carvacrol conjugation can be seen due to 
appearance of sp3 C-H stretches at 2957 cm-1 and is nearly identical to the carvacrol oil 
IR. Taken together with the observations from confocal microscopy, carvacrol serves to 
not only enable inter-gelatin crosslinking through oil-templating, but conjugates onto 
gelatin imparting more hydrophobicity and allow gelatin to better transverse the oil core. 
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Figure 5.3. ATR-FTIR spectra. a) carvacrol oil, b) inter-gelatin crosslinking, c) negative 
control, d) GEL-XCs. Observed crosslinking/conjugation signatures and their proposed 
structures are highlighted in purple and teal respectively. 
5.2.4 Stability of GEL-XCs 
After determining GEL-XCs physical and chemical composition, we next 
explored their stability in a complex biological environment. A successful therapeutic 
must maintain their activities when translating from in vitro to in vivo.25 One challenge 
with nano-assemblies is loss of their activity in vivo due to protein adsorption, causing 
aggregation or precipitation.26 We explored GEL-XCs stability in 10% fetal bovine serum 
(FBS) (Figure 5.4) using DLS and compared its size to the standard size found in 150 
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mM phosphate buffer saline (PBS). After incubating GEL-XCs in 10% FBS for one hour, 
a size increase of ~30 nm was observed, likely due to serum protein adsorption. Prior 
literature indicates that carvacrol can induce protein unfolding of BSA and it is this 
process that may occur on the surface of GEL-XCs.27 Compared to our previous synthetic 
analogs, GEL-XCs are less stable, however gelatin is a better suited stabilizer for its high 
biocompatibility and may even become sequestered during wound healing processes.28 
Future experiments are needed to better ascertain this hypothesis. 
 
Figure 5.4. GEL-XC Stability. Stability of GEL-XCs in high ionic strength (black) for 24 
hours or similarly with a 10% addition of fetal bovine serum (blue) for one hour.  
5.2.5 Biological Activity of GEL-XCs 
Next, we monitored GEL-XCs activity towards pathogenic biofilms, generated 
from Gram-Negative and Gram-Positive bacteria (Figure 5.5). Four bacterial strains of 
clinical isolates, Staphylococcus aureus (CD-489, a methicillin-resistant strain), 
Pseudomonas aeruginosa (CD-1006), Escherichia coli (CD-2), and Enterobacter cloacae 
124 
 
(E. cloacae, CD-1412) complex were chosen to be tested as their associated infections 
are becoming more challenging to eliminate with traditional antibiotic therapy. GEL-
XCs, along with its individual components at similar concentrations as controls were 
incubated with 1-day-old biofilms for three hours, washed, and their viabilities analyzed. 
Individual components, gelatin and carvacrol, showed almost no antimicrobial effect. 
However, when combined into the GEL-XCs nano-assembly, impressive killing effect 
was observed, performing similarly to previous synthetic phytochemical assemblies. 
Taken together, natural components that previously showed no antimicrobial activity can 
be assembled through nanotechnology insights to generate potent broad-spectrum 
antimicrobials and eliminate difficult to treat infections found in hospital settings. 
125 
 
 
Figure 5.5. Activity of GEL-XCs against pathogenic biofilms. Individual components of 
GEL-XCs show marginal or no antimicrobial effect. Combination of these components 
into GEL-XCs incubated at various concentrations penetrate and eliminate pathogenic 
bacterium enclosed within. Results are an average of three experiments. Error bars are 
representative of their standard deviation. 
5.2.6 Scalability of GEL-XCs 
Fighting MDR pathogens, from a therapeutic standpoint, must take into 
consideration sustainability. Given the dangers of MDR, not only should future therapies 
eliminate these pathogens without accumulating resistance but be manufactured from 
easily accessible materials. Furthermore, these materials should not be a large burden 
from a financial and economic view. GEL-XCs shows great promise to satisfy the 
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conditions of sustainability as gelatin, riboflavin, and carvacrol oil are some of the most 
easily accessed materials and are well-documented as food-grade ingredients. Therefore, 
GEL-XCs can be considered a nutraceutical platform that could be implemented beyond 
biomedical and integrated into agriculture, food, and textile industries. However, these 
industries require a significantly greater amounts of material than biomedical and GEL-
XCs may easily satisfy this need. Emulsification processes are well-documented to scale 
linearly, even under large-scale manufacturing practices. Therefore, we hypothesized that 
as long as each parameter during the emulsification/crosslinking process is scaled 
appropriately, GEL-XCs could be produced in large amounts. Using a two-liter scale 
homogenizer and a proprietary UVA apparatus, Figure 5.6 shows the successful result of 
scaling over 4,000 times our original 500 µL formulation. Current testing is ongoing, 
however the stability of large-scale GEL-XCs is remarkably the same to our research 
scale (currently, one year). GEL-XCs has been preliminary shown to satisfy the needs of 
scalability for industries that have greater material requirements. 
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Figure 5.6. Image of 2 L scale GEL-XC production. Emulsification process was found to 
scale linearly between 500 µL – 2 L.  
5.3. Conclusions 
In conclusion, we demonstrate here nature inspired/derived crosslinked gelatin-
stabilized nanocomposites demonstrating similar physical, morphological, and 
bioactivities to previous synthetic phytochemical emulsions. These natural composites 
were found to have great shelf-life and could be easily scaled to industrial standards at a 
fraction of the cost of prior synthetic stabilizers. Furthermore, these phytochemical 
vehicles were found to have similar antimicrobial capabilities of previous analogs and 
were found to have broad-spectrum potency towards pre-formed biofilms, even biofilms 
formed from MDR species. Interestingly, the use of gelatin as a stabilizer generates 
unique hydrogel-like appendages external to the oil core, enabling the possibility of inter-
particle crosslinking, potentially opening new antimicrobial applications beyond a 3D 
aqueous matrix. Most critically, the work presented within is, to the best of our 
knowledge, the first demonstration at generating sustainably relevant phytochemical 
antimicrobials to combat the impending dangers of MDR in biomedical, agriculture, 
food, and textile industries. This PhD candidate looks forward to continuing the 
translation of these nano-assemblies from the research setting into the hands of 
commercial end-users. 
5.4. Experimental Protocols 
5.4.1 Materials and Methods 
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All reagents and materials were purchased from Fisher Scientific and used as 
received. Dulbecco’s Modified Eagle’s Medium (DMEM) (DMEM; ATCC 30-2002) and 
fetal bovine serum (Fisher Scientific, SH3007103) were used in cell culture.  
5.4.2 Preparation of GEL-XCs 
Stock nanocomposite solutions were prepared in 0.6 ml Eppendorf tubes. To 
prepare the stock GEL-XC emulsions, 3 µL of carvacrol oil (containing 0.1 wt% riboflavin) 
was added to 497 µL of Milli-Q H2O containing 3mg/ml of gelatin and emulsified in an 
amalgamator for 50 s. Afterwards, tubes were subjected to 365 nm light from a handheld 
UV lamp for 20 minutes. The emulsions were allowed to rest overnight prior to use. 
5.4.3 Biofilm Formation 
Bacteria were inoculated in LB broth at 37°C until stationary phase. The cultures 
were then harvested by centrifugation and washed with 0.85% sodium chloride solution 
three times. Concentrations of resuspended bacterial solution were determined by optical 
density measured at 600 nm. Seeding solutions were then made in M9 to reach OD600 of 
0.1. 100 μL of the seeding solutions were added to each well of the microplate. M9 medium 
without bacteria was used as a negative control. The plates were covered and incubated at 
room temperature under static conditions for a desired period. Planktonic bacteria were 
removed by washing with PB saline three times.  
Varied v/v % of GEL-XCs, made in M9 medium, were incubated with the biofilms 
for 3 h. Biofilms were washed with phosphate buffer saline (PBS) three times and viability 
was determined using an Alamar Blue assay. M9 medium without bacteria was used as a 
negative control.  
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CHAPTER 6 
ENGINEERED POLYMER NANOPARTICLES WITH 
UNPRECEDENTED ANTIMICROBIAL PROPERTIES FOR 
THE TREATMENT OF MULTIDRUG-RESISTANT 
BACTERIAL AND BIOFILMS INFECTIONS 
 
 
6.1. Introduction 
Overusing antibiotics have created “superbugs” such as methicillin-resistant 
Staphylococcus aureus (MRSA) and particularly hard to treat Gram-negative species that 
pose a serious threat to global health due to treatment failure and high mortality rates.1 
While planktonic bacteria can frequently cause acute infections resulting in a threatening 
situation such as sepsis, the threat is further aggravated by chronic infections from 
biofilms.2,3 Biofilm-associated infections frequently occur on medical implants and 
indwelling devices such as catheters, prosthesis and dental implants. Biofilm infections can 
also occur on or around dead tissues leading to endocarditis and chronic wound 
infections.4,5 These resilient infections are challenging to treat as biofilms exhibit high 
resistance towards a host’s immune response and traditional antimicrobial therapies.6,7 
Current biofilm treatment techniques require aggressive antibiotic therapy coupled with 
debridement of infected tissue. However, this standard treatment incurs high treatment 
costs and low patient compliance due to the invasive nature of the treatment.8 The issue is 
exacerbated by the increasing number of antibiotic-resistant bacterial strains, further 
impairing their therapeutic effectiveness.9 
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Antimicrobial peptides (AMPs) have recently emerged as an alternative to 
conventional antibiotic therapy, exhibiting broad spectrum activity against antibiotic-
resistant bacteria.10,11 While some AMPs have demonstrated high therapeutic indices 
(selectivity towards bacterial cells) of ~900 and ~3,30012 against planktonic bacteria,  these 
α-helical peptides are susceptible to proteolytic degradation within the patient, greatly 
reducing their efficacy.13,14 Additionally, the cost and labor intensive requirements of 
sequence-specific peptides further limits their clinical practicality. As an alternative to 
AMPs, host-defense peptide mimicking synthetic polymers have been designed to 
demonstrate broad spectrum activity against microbes.15,16,17,18,19,20 However, high toxicity 
towards mammalian cells resulting in low therapeutic indices (ranging from ~1-15015-19) 
have impaired their practical applications in clinical settings. Limited studies have 
demonstrated synthetic polymers with promising therapeutic selectivity,21,22,23,24 however 
they have primarily focused on the treatment of planktonic microbes, overlooking their 
more drug-resistant biofilm counterparts. To the best of our knowledge, synthetic polymers 
exhibiting high biofilm efficacy while maintaining low toxicity towards mammalian cells 
have not been reported. Therefore, designing polymers possessing these properties will be 
invaluable towards developing highly effective therapeutics for bacterial-based infections. 
Here, we report engineered polymers that can effectively eradicate pre-formed 
biofilms while maintaining a high therapeutic index against red blood cells (RBCs). We 
hypothesized that the therapeutic window of cationic polymers can be regulated by varying 
their hydrophobic properties, similar to hydrophobic residues present in the active sites of 
antimicrobial peptides.  We synthesized a library of quaternary ammonium 
poly(oxanorborneneimides) possessing different degrees of hydrophobicity and screened 
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their antimicrobial and hemolytic activities. These polymers form 10-15 nm nanoparticles 
in aqueous solution, increasing their overall cationic charge and molecular mass. We 
observed that longer hydrophobic alkyl chains that bridge the cationic head group and 
polymer backbone greatly enhances toxicity against planktonic bacteria while maintaining 
excellent hemolytic activities towards RBCs (Therapeutic Index ~ 5000). These 
nanoparticles readily penetrate biofilms and eradicate pre-formed biofilms while still 
maintaining high therapeutic indices (~120). Polymeric NPs (PNPs) demonstrated a 6-fold 
log reduction in bacterial colonies, when tested in a biofilm-mammalian cell coculture 
model. Most notably, we observed that bacteria did not develop any resistance against 
PNPs even after 20 serial passages. Overall, our engineered polymeric nanoparticle 
platform shows strong potential as an infectious disease therapeutic and simultaneously 
provides a rational approach to design novel antimicrobials for sustainably combating 
bacterial infections. 
 
6.2. Results 
Norbornene-based amphiphilic polymers with varying quaternary nitrogen side 
chains have been previously demonstrated to have excellent antimicrobial properties.25,26,27 
Additionally, well-controlled living chain-growth polymerization kinetics, ease of 
modulation, and scalability further highlights their value as a promising therapeutic 
platform.28,29,30 Hence, we adopted this backbone to design our cationic amphiphilic 
antimicrobial polymers. Distribution of hydrophobic moieties on antimicrobial 
macromolecules plays a pivotal role in determining their bactericidal activity.31,32 We 
generated a library of oxanorbornene polymers (Figure 6.1) with varying unbranched alkyl 
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chains both bridging the cationic head group and the polymer backbone itself to 
systematically determine the most effective antimicrobial polymer formulation. Notably, 
polymers containing a bridged undecyl alkyl chain spontaneously self-assemble into 
cationic PNPs (~13 nm) in aqueous solutions as confirmed by transmission electron 
microscopy (TEM, Figure 6.1d, Supporting Figure 6.7), dynamic light scattering (DLS, 
Figure 6.1e) and Förster resonance energy transfer (FRET) experiments (Figure 6.1.f, 
Structural details of dye-tagged polymer is in Supporting Figure 6.6). Dilution experiments 
of encapsulated Nile Red within P5 NPs indicated a critical micelle concentration of < 2.5 
µM (Supporting Figure 6.11).33 
 
Figure 6.1. Molecular structures of a) oxanorbornene polymer derivatives. b) MIC values 
of polymer derivatives with different hydrophobic chain lengths. Log P represents the 
calculated hydrophobic values of each monomer c) Schematic representation depicting 
self-assembly of P5-homopolymers. Characterization of P5 NPs using TEM imaging and 
DLS measurement. d) Graph for FRET experiments between P5-Rhodamine Green and 
P5-TRITC indicating formation of polymeric NPs.   
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Cationic PNPs were screened for their antimicrobial activity against an 
uropathogenic strain of Escherichia coli (CD-2), using broth dilution methods to evaluate 
their minimal inhibitory concentrations (MICs).34 We observed a 1000-fold increase in the 
antimicrobial activity of polymeric nanoparticles upon increasing the hydrophobicity of 
the alkyl chain bridging the backbone and cationic headgroup (Figure 6.1b). P1-P4 with 
smaller internal alkyl chain displayed MICs of 64 µM, while P5 and P6 with more 
hydrophobic (11 C-chain) inhibited bacteria growth at 0.064 µM. We further extended the 
hydrophobicity on the cationic headgroup of the polymers and monitored the change in 
antimicrobial activity. We determined that the MICs of PNPs did not change significantly 
upon increasing the hydrophobicity at the cationic headgroup (Figure 6.2a). Similar 
behavior has also been reported in AMPs where the location of hydrophobic residues along 
with overall hydrophobicity determines their antimicrobial activity.35,36 Subsequently, we 
performed hemolysis assays on human RBCs with our most potent polymer P5 and P6 and 
calculated their HC50 (concentration that causes 50% lysis of RBCs) to determine their 
biocompatibility.37 MIC and HC50 values were used to calculate a therapeutic index (T.I = 
HC50/MIC) of  PNPs against planktonic bacteria. PNPs (P5- P6) with undecyl-bridging 
alkyl chains showed minimal hemolytic character (Figure 6.2.b).  The highest antimicrobial 
efficiency was observed with P5 NPs, with an MIC of 64 nM (0.9 µg.ml-1) against E. coli. 
P5 NPs showed little hemolytic character (HC50, >150 µM, 4700 µg.ml-1) providing an 
unprecedented therapeutic index of more than 5000, 10-fold higher than previous polymer-
based antimicrobials. Having established P5 NPs are acutely non-toxic, we next 
investigated their chronic toxicity in relation to inflammatory cytokine responses from 
macrophage RAW 264.7 cells (Figure 6.2c). NP concentrations up to 2µM showed no 
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significant toxicity or tumor necrosis factor alpha (TNF-α) cytokine expression (Figure 
6.2d), suggesting in vitro immunocompatibility with mammalian immune cells.38 
 
Figure 6.2. a) Graph showing minimum inhibitory concentrations (MIC) and structure 
details of oxanorbornene derivatives with different hydrophobicity of the cationic 
headgroups. Log P represents the calculated hydrophobic values of each monomer. b) 
Hemolytic activity of PNPs at different concentrations indicate their non-hemolytic 
behavior at relevant therapeutic concentrations. c) Cytotoxicity of P5- PNPs against Raw 
264.7 macrophage cells. d) TNF-α secretion of Raw 264.7 cells in the presence of PNPs. 
Lipopolysaccharide (LPS) was used as a positive control. 
 
We next tested our most potent P5 NPs against multiple uropathogenic clinical 
isolates (Table 6.1) to establish its broad-spectrum activity.  P5 NPs suppressed bacterial 
proliferation at concentrations ranging from 64-128 nM (0.9 µg.ml-1 – 1.8 µg.ml-1), similar 
or lower to previously reported antimicrobial polymers. These polymers showed similar 
antimicrobial activity against 5 clinical isolates of E. coli with different susceptibilities to 
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clinical antibiotics (resistant to 1-17 drugs), indicating their ability to evade common 
mechanisms of bacterial resistance. Additionally, engineered polymers were effective 
against clinical isolates of Gram-negative P. aeruginosa and E. cloacae complex. 
Similarly, Gram-positive strains of S. aureus were susceptible to P5 NPs including the 
highly virulent strain of methicillin-resistant S. aureus (MRSA). 
 
Table 6.1. Minimum inhibitory concentrations and therapeutic indices of P5 NPs against 
multiple uropathogenic clinical isolate bacterial strains. Therapeutic indices are calculated 
with respect to red blood cells. 
 
Due to the highly cationic and hydrophobic nature of our PNPs, we hypothesized 
they can be particularly effective in disrupting bacterial cell membranes.39,40 We used a 
propidium iodide (PI) staining assay to support our hypothesis. PI can only stain cells 
which have compromised membranes, allowing them to bind with nucleic acids and 
generate red fluorescence.41,42 Pathogenic E. coli (CD-2), S. aureus (CD-489) and non-
pathogenic P. aeruginosa (ATCC 19660) were treated with 1 µM of P5 NPs for 3 hours at 
37 ºC and subsequently stained with PI before imaging. The confocal images (Figure 6.3b) 
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clearly show that PNPs mechanism of action leads to bacterial membrane disruption in all 
three species, regardless of membrane composition or pathogenicity.     
 
Figure 6.3. Confocal micrographs. a) Representative 3D projection of confocal image 
stacks of E2-Crimson (Red Fluorescent Protein) expressing E. coli DH5α biofilm after 1 h 
treatment with P5-Rhodamine Green at 1µM concentration. The panels are projection at 
0º, 60º and 90º angle turning along X axis. Scale bars are 30 μm. b) Confocal images of E. 
coli (CD-2), S. aureus (MRSA, CD-489) and P. aeruginosa (ATCC 19660) stained with 
Propidium Iodide (PI) after treatment with PNPs. Scale bars are 30µm. 
 
After establishing the efficacy of our NPs against bacterial “superbugs”, we tested 
their efficacy against more resilient bacterial infections- “biofilms”. Biofilms produce 
extracellular polymeric substance, acting as a barrier against therapeutics. Penetration and 
accumulation of therapeutics inside biofilms is crucial for effective therapy of these 
infections.43,44 Hence, we used confocal microscopy to examine the ability of PNPs to 
penetrate biofilms. We treated biofilms formed by E. coli expressing DS Red (a red 
fluorescent protein) with P5 NPs functionalized with Rhodamine Green fluorescent dyes. 
As shown in Figure 6.3a, fluorescently labeled nanoparticles could readily penetrate and 
disperse throughout the biofilms (Supporting Figure 6.8), indicating their ability to be an 
effective anti-biofilm agent.  
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Figure 6.4. Biofilm viability towards P5 NPs. Viability of 1-day-old (a) P. aeruginosa 
(ATCC-19660), (b) P. aeruginosa (CD-1006), (c) S. aureus(CD-489), and (d) En. cloacae 
complex (CD-1412) biofilms after 3 h treatment with P5 NPs. The data are average of 
triplicates, and the error bars indicate the standard deviations. TI is the therapeutic index 
relative to MBEC90 and hemolysis. 
 
Next, we investigated the therapeutic ability of P5 NPs against pre-formed bacterial 
biofilms. We chose a laboratory strain of P. aeruginosa (ATCC 19660) and 3 
uropathogenic clinical isolates, P. aeruginosa (CD-1006), En. cloacae complex (CD-1412) 
and S. aureus (CD-489, a methicillin-resistant strain). As shown in Figure 6.4, P5 NPs 
demonstrate minimum concentrations to eradicate 90% of biofilms (MBEC90) ranging 
from 1-3 µM, providing unprecedented therapeutic indices ranging from 60-165 for 
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biofilms (TI = HC50/MBEC90). Nanoparticles could treat both Gram-negative (P. 
aeruginosa, and En. cloacae complex) and Gram-positive (S. aureus) bacterial strains, 
further highlighting their broad-spectrum activity against biofilms. Notably, P5 NPs 
demonstrated similar efficacy in treating MDR (CD-489, CD-1412) and non-resistant 
strains (CD-1006, ATCC 19660), suggesting their value as a promising therapeutic 
alternative to traditional antibiotics.  
The ability to eradicate biofilms on biomedical surfaces such medical implants and 
indwelling devices is a critical capability. However, treating biofilm infections on human 
tissues or organs is more challenging and relevant to medical settings. Biofilm infections 
on wounds significantly impair the healing process regulated by fibroblast skin cells.45 We 
used an in-vitro coculture model comprised of mammalian fibroblast cells with biofilms 
grown over them.46,47,48 First, we investigated P5 NPs compatibility with mammalian NIH 
3T3 fibroblast cells at similar concentrations used to eradicate pre-formed biofilms and 
observed no significant toxicity (Supporting Figure 6.9). Next, P. aeruginosa bacteria were 
seeded on a confluent monolayer of NIH 3T3-fibroblast cells overnight to generate 
biofilms prior to treatment. The cocultures were treated with P5 NPs for 3 hours, washed, 
and the viabilities of both bacteria and fibroblasts determined. As shown in Figure 6.5a, a 
4-6-fold log reduction (99.5%-99.99%) in bacterial colonies was observed at 
concentrations ranging from 7.5-15 µM, while the fibroblast viability was still maintained.  
142 
 
 
Figure 6.5. a) Viability of 3T3 fibroblast cells and E. coli biofilms in the coculture model 
after 3 h treatment with P5 NPs. Scatters and lines represent 3T3 fibroblast cell viability. 
Bars represent log10 of colony forming units in biofilms. The data are average of triplicates 
and the error bars indicate the standard deviations. b) Resistance development during serial 
passaging in the presence of sub-MIC levels of antimicrobials. The y axis is the highest 
concentration the cells grew in during passaging. The figure is representative of 3 
independent experiments. 
 
Bacteria can acquire resistance quickly towards antibiotics and other 
antimicrobials, minimizing their therapeutic prospects in clinical settings. We subjected 
uropathogenic E. coli (CD-2) to multiple serial passages of sub-MIC (66% of MIC) 
concentrations of P5 NPs to investigate if resistance towards our polymer nanoparticles 
would occur.27 The resulting bacterial population was defined as the first generation, 
harvested, and its MIC was evaluated. Subsequently, a second generation was produced by 
exposing first generation with 66% MIC dosage of polymers. As shown in Figure 6.5b, it 
was observed that even at the 20th serial passage (~1,300 bacterial generations) of CD-2, 
E. coli was still susceptible to 128 nM of P5 NPs, as compared to the zeroth generation. 
Similar experiments were conducted on ciprofloxacin (quinolone), ceftazidime (β-lactam) 
and tetracycline, clinically relevant antibiotics. Respectively, there was a 33,000, 4,200 and 
256-fold increase in the MICs of antibiotics against CD-2 E. coli. This significant result 
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indicates the killing mechanism of our engineered nanoparticles significantly undermine 
the onset of resistance development in bacteria. Notably, we have demonstrated our 
polymeric nanoparticles remain un-resistant towards bacteria longer than previously 
reported polymer-based nanomaterials49 (~600 generations – A. baumannii FADDI-
AB156) and comparable to a recently discovered and novel antibiotic, teixobactin (~1,300 
generations – S. aureus ATCC 29213).50 
 
6.3. Conclusions 
We have reported here a novel therapeutic platform to combat MDR bacterial and 
biofilm infections using engineered polymeric nanoparticles. Our study demonstrates the 
ability to modulate antimicrobial activity and therapeutic efficacy of polymeric NPs by 
incorporating hydrophobic alkyl groups in polymer side-chains. Cationic hydrophobic 
polymers can self-assemble to form polymeric NPs and demonstrate excellent efficiency 
in combating planktonic superbugs as well as their more drug-resistant biofilm 
counterparts. Their ability to penetrate and eradicate biofilms can foster a therapeutic 
advancement that can fundamentally alter the treatment strategy of these dangerous 
infections. Notably, bacteria do not develop resistance against polymeric NPs for 20 serial 
passages, an elusive feat for clinical antibiotics. Taken together, polymer NP-based 
antimicrobial therapy has the potential to provide an effective platform to combat bacterial 
infections while circumventing standard antibiotic resistance pathways. Moreover, our 
study provides a crucial insight for designing next-generation antimicrobials with 
implications in a wide-range of planktonic and biofilm-related infections. 
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6.4. Experimental Protocols 
6.4.1 Synthesis of Grubbs 3rd Generation Catalyst 
Grubbs 3rd generation catalyst was synthesized as described in previously published 
reports.51 Detailed synthesis can be found in the Supporting Information. 
6.4.2 Determination of Antimicrobial Activities of Cationic Polymers 
Bacteria were cultured in LB medium at 37 ˚C and 275 rpm until stationary phase. 
The cultures were then harvested by centrifugation and washed with 0.85% sodium 
chloride solution for three times.27 Concentrations of resuspended bacterial solution were 
determined by optical density measured at 600 nm. M9 medium was used to make dilutions 
of bacterial solution to a concentration of 1 × 106 cfu/mL. A volume of 50 μL of these 
solutions was added into a 96-well plate and mixed with 50 μL of polymer solutions in M9, 
giving a final bacterial concentration of 5 × 105 cfu/mL. Polymer concentration varied in 
half fold per a standard protocol, ranging from 1024 to 4 nM. A growth control group 
without polymers and a sterile control group with only growth medium were carried out at 
the same time. Incubation of the polymers with bacteria was performed for 16 hours. 
Cultures were performed in triplicates, and at least two independent experiments were 
repeated on different days. The MIC is defined as the lowest concentration of polymer that 
inhibits visible growth as observed with the unaided eye.52 
6.4.3 Determination of Hemolysis of Cationic Polymers 
We used the previously established protocol to conduct hemolysis assays on Red 
Blood Cells.28 Citrate-stabilized human whole blood (pooled, mixed gender) was 
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purchased from Bioreclamation LLC, NY and processed as soon as received. 10 mL of 
phosphate buffered saline (PBS) was added to the blood and centrifuged at 5000 r.pm. for 
5 minutes. The supernatant was carefully discarded and the red blood cells (RBCs) were 
dispersed in 10 mL of PBS. This step was repeated at least five times. The purified RBCs 
were diluted in 10 mL of PBS and kept on ice during the sample preparation. 0.1 mL of 
RBC solution was added to 0.4 mL of polymer solution in PBS in a 1.5 mL centrifuge tube 
(Fisher) and mixed gently by pipetting. RBCs incubated with PBS and water was used as 
negative and positive controls, respectively. All polymer samples as well as controls were 
prepared in triplicate. The mixture was incubated at 37 ˚C for 30 minutes while shaking at 
150 r.p.m. After incubation period, the solution was centrifuged at 4000 r.p.m. for 5 
minutes and 100 μL of supernatant was transferred to a 96-well plate. The absorbance value 
of the supernatant was measured at 570 nm using a microplate reader (SpectraMax M2, 
Molecular devices) with absorbance at 655 nm as a reference. The percent hemolysis was 
calculated using the following formula: 
 % 𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻 =  (𝑆𝑆𝑆𝑆𝐻𝐻𝑆𝑆𝐻𝐻𝐻𝐻 𝐴𝐴𝐴𝐴𝐻𝐻𝐻𝐻𝐴𝐴𝐴𝐴𝑆𝑆𝐴𝐴𝐴𝐴𝐻𝐻 − 𝑁𝑁𝐻𝐻𝑁𝑁𝑆𝑆𝑁𝑁𝐻𝐻𝑁𝑁𝐻𝐻 𝐶𝐶𝐻𝐻𝐴𝐴𝑁𝑁𝐴𝐴𝐻𝐻𝐻𝐻 𝐴𝐴𝐴𝐴𝐻𝐻𝐻𝐻𝐴𝐴𝐴𝐴𝑆𝑆𝐴𝐴𝐴𝐴𝐻𝐻)(𝑃𝑃𝐻𝐻𝐻𝐻𝐻𝐻𝑁𝑁𝐻𝐻𝑁𝑁𝐻𝐻 𝐶𝐶𝐻𝐻𝐴𝐴𝑁𝑁𝐴𝐴𝐻𝐻𝐻𝐻 𝐴𝐴𝐴𝐴𝐻𝐻𝐻𝐻𝐴𝐴𝐴𝐴𝑆𝑆𝐴𝐴𝐴𝐴𝐻𝐻 − 𝑁𝑁𝐻𝐻𝑁𝑁𝑆𝑆𝑁𝑁𝐻𝐻𝑁𝑁𝐻𝐻 𝐶𝐶𝐻𝐻𝐴𝐴𝑁𝑁𝐴𝐴𝐻𝐻𝐻𝐻 𝐴𝐴𝐴𝐴𝐻𝐻𝐻𝐻𝐴𝐴𝐴𝐴𝑆𝑆𝐴𝐴𝐴𝐴𝐻𝐻) ∗ 100 
 
6.4.4 Macrophage Cell Studies and TNF-alpha Secretion 
RAW 264.7 macrophage cell line was purchased from American Type Culture 
Collection (ATCC, Manassas, VA). Roswell Park Memorial Institute media (RPMI 1640) 
supplemented with 10% fetal bovine serum, 1% antibiotics (100 µg/ml penicillin and 100 
µg/ml streptomycin) and sodium pyruvate, was used for cell culture. The cells were 
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incubated at 37 °C under a humidified atmosphere of 5% CO2. The cells were cultured 
once every four days under the above-mentioned conditions.  
6.4.5 Polymer Nanoparticles and LPS Treatment 
These studies were conducted as per the previously reported protocols.53 Briefly, to 
evaluate the effect of polymer on the immune system, 1.0 × 105 of RAW 264.7 cells were 
cultured in a 24-well plate for 24 h. Then, cells were washed once with cold PBS and 
treated with different concentration of polymer for 3 h or 24h. The macrophage with 
100ng/ml of lipopolysaccharide were the positive control. At the end of incubation, culture 
media was collected for TNF-α level measurement by ELISA (R&D Systems, MN, USA). 
Experiments were performed in triplicate.  
6.4.6 Propidium Iodide Staining Assay 
E. coli CD-2, P. Aeruginosa ATCC19660 and MRSA CD-489 (1 × 108 cfu/mL) 
were incubated with 1 µM P5 NPs in M9 media at 37 ˚C and 275 rpm for 3 h. The bacteria 
solutions were then mixed with PI (2 μM) and incubated for 30 min in dark. Five 
microliters of the samples were placed on a glass slide with a glass coverslip and observed 
with a confocal laser scanning microscopy, Zeiss 510 (Carl Zeiss, Jena, Germany) using a 
543-nm excitation wavelength.  
6.4.7 Biofilm Formation and Treatment 
Bacteria were inoculated in lysogeny broth (LB) medium at 37 ˚C until stationary 
phase. The cultures were then harvested by centrifugation and washed with 0.85% sodium 
chloride solution three times. Concentrations of resuspended bacterial solution were 
determined by optical density measured at 600 nm. Seeding solutions were then made in 
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M9 medium to reach an OD600 of 0.1. A 100 μL amount of the seeding solutions was added 
to each well of the 96-well microplate. The plates were covered and incubated at room 
temperature under static conditions for 1 day. The stock solution of polymers was then 
diluted to the desired level and incubated with the biofilms for 3 hours at 37˚C. Biofilms 
were washed with phosphate buffer saline (PBS) three times and viability was determined 
using an Alamar Blue assay. Minimal M9 medium without bacteria was used as a negative 
control.37 
6.4.8 Biofilm-3T3 Fibroblast Cell Co-culture 
Co-culture was performed using the previously reported protocol.54 A total of 
20000 NIH 3T3 (ATCC CRL-1658) cells were cultured in Dulbecco’s modified Eagle 
medium (DMEM; ATCC 30-2002) with 10% bovine calf serum and 1% antibiotics at 37 
°C in a humidified atmosphere of 5% CO2. Cells were kept for 24 h to reach a confluent 
monolayer. Bacteria (P. aeruginosa) were inoculated and harvested as mentioned above. 
Afterward, seeding solutions 108 cells/mL were inoculated in buffered DMEM 
supplemented with glucose. Old medium was removed from 3T3 cells followed by addition 
of 100 μL of seeding solution. The cocultures were then stored in a box humidified with 
damp paper towels at 37 °C overnight without shaking. Polymer NPs and other control 
solutions were diluted in DMEM media prior to use to obtain the desired testing 
concentrations. Old media was removed from coculture, replaced with freshly prepared 
testing solutions, and incubated for 3 h at 37 °C. Cocultures were then analyzed using an 
LDH cytotoxicity assay to determine mammalian cell viability using manufacturer’s 
instructions.55 To determine the bacteria viability in biofilms, the testing solutions were 
removed and cocultures were washed with PBS. Fresh PBS was then added to disperse 
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remaining bacteria from biofilms in coculture by sonication for 20 min and mixing with 
pipet. The solutions containing dispersed bacteria were then plated onto agar plates, and 
colony forming units were counted after incubation at 37 °C overnight. 
6.4.9 Resistance Development 
E. coli CD-2 was inoculated in M9 medium with 85 nM (2/3 of 128 nM, MIC) of 
P5 NPs at 37 ˚C and 275 rpm for 16 h (~ 64 bacterial generations for 1 serial passage). The 
culture was then harvested and tested for MIC as describe above. E. coli CD-2 was cultured 
without polymer as well every time as a control for comparison of MICs. In the case of P5 
NPs, 20 serial passages were performed giving ~ 1,300 generations. 
 
6.5. Supporting Figures 
6.5.1 Oxanorbornene Monomer Synthesis 
Note: Generation of C2 and C6-bridged polyoxanorbornene polymers can be successfully 
made using the same procedures used to generate C11-bridged polymers however 
replacing 11-bromoundecanol with bromoethanol or 6-bromohexanol, respectively. 
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Synthesis of 1. In a pressure tube, furan (4.5ml, 61.7mmol, 1.5eq) and maleimide (4.0g, 
41.1mmol, 1.0eq) were added in addition to 5ml of diethyl ether. The tube was sealed and 
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heated at 100oC overnight. Afterwards, the pressure tube was cooled to r.t. and the formed 
solid was removed, filtered, and washed with copious amounts of diethyl ether to isolate 1 
as a white solid (95% yield) and was used without further purification. 1H NMR (400MHz, 
MeOD) 11.14 (s, 1H), 6.52 (s, 2H), 5.12 (s, 2H), 2.85 (s, 2H). 
Synthesis of 2. To a 250ml round bottom flask equipped with a stir bar was added 60ml of 
DMF. Next, 1 (3.76g, 22.7mmol, 1.0eq) was added along with potassium carbonate 
(12.59g, 91.1mmol, 4.0eq). The reaction mixture was heated at 50oC for five minutes. 
Finally, potassium iodide (0.68g, 4.5mmol, 0.2eq) and 11-bromoundecanol (6.00g, 
23.90mmol, 1.05eq) were added and stirred at 50oC overnight. Afterwards, the reaction 
mixture was cooled to room temperature, diluted to 150ml with ethyl acetate and washed 
with water (7x, 50ml) and brine (1x, 50ml). The organic layer was dried with sodium 
sulfate, filtered, and rotovaped to yield 2. 2 was purified by sonication of the rotovaped 
solid in hexanes and filtered (82% yield). 1H NMR (400MHz, CDCl3) 6.44 (s, 2H), 5.19 
(s, 2H), 3.55, (t, 2H), 3.49 (t, 2H), 2.79 (s, 2H), 1.9 (s, 1H), 1.39 (m, 4H), 1.2 (m, 14H). 
Synthesis of 3. To a 250ml round bottom flask equipped with a stir bar was added 2 (2.64g, 
7.87mmol, 1.0eq). Next, DCM (100ml) was added along with tetrabromomethane (3.13g, 
9.44mmol, 1.2eq). The reaction was cooled to 0oC using an ice bath. Finally, 
triphenylphosphine was added in portions (2.47g, 9.44mmol, 1.2eq) and allowed to stir for 
three hours. Afterwards, the reaction mixture was rotovaped and ethyl ether was added 
(200ml) and placed in the freezer for 2 hours to precipitate out triphenylphosphine oxide. 
The reaction mixture was filtered, and the filtrate was rotovaped. Column chromatography 
was performed to yield 3, a white solid (79% yield). 1H NMR (400MHz, CDCl3) 6.51 (s, 
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2H), 5.27 (s, 2H), 3.45 (t, 2H), 3.41 (t, 2H), 2.83 (s, 2H), 1.85 (q, 2H), 1.55 (q, 2H), 1.41 
(q, 2H), 1.29 (m, 12H). 
6.5.2 Oxanorbornene Polymer Synthesis 
Synthesis of 4. To a 10ml pear-shaped air-free flask equipped with a stir bar was added 3 
(800mg, 2.0mmol, 1.0eq) and 4ml of DCM. In a separate 10ml pear-shaped air-free flask 
was added Grubbs 3rd generation catalyst56 (35.4mg, 0.04mmol, 0.02eq) and 1ml DCM. 
Both flasks were sealed with septa and attached to a schlenk nitrogen/vaccum line. Both 
flasks were freeze-pump-thawed three times. After thawing, Grubbs 3rd generation catalyst 
was syringed out and quickly added to the flask containing 3 and allowed to react for 
10min. After the allotted time, ethyl vinyl ether (200 µL) was added and allowed to stir for 
15 minutes. Afterwards, the reaction was diluted to two times the volume and precipitated 
into a heavily stirred solution of hexane (300ml). The precipitated polymer was filtered 
and dissolved into tetrahydrofuran (THF). The polymer was precipitated again into hexane 
and filtered to yield 4. MW = 25,698, PDI = 1.04 (determined by THF-GPC using a 
Polystyrene calibration curve) 1H NMR (400MHz, CDCl3) 6.0 (br, 1H), 5.7 (br, 1H), 4.95 
(br, 1H), 4.4 (br, 1H), 3.4 (br, 2H), 3.25 (br, 2H), 1.79 (q, 2H), 1.5 (br, 2H), 1.34 (br, 2H), 
1.2 (br, 14H). 
6.5.3 Synthesis of 5 Quaternary Ammonium Polymers 
To generate the library of quaternary ammonium poly(oxanorborneneimides), 4 (50mg) 
was added to 20ml vials equipped with a stir bar. Next, excess of the necessary tertiary 
amines was added (10ml of a 1M trimethylamine solution in THF, all other amines were 
200mg) to the vial and purged with nitrogen. First stage of the reactions involved stirring 
for 30 minutes at 80oC. The polymers precipitated during this time. Half of the THF was 
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evaporated and replaced with methanol which re-dissolved the polymers. The reaction was 
allowed to proceed overnight at 50oC. Afterwards, the solvent was completely evaporated, 
washed with hexane 2 times, and dissolved into a minimal amount of water. The polymers 
were added to 10,000 MWCO dialysis membranes and allowed to stir for 3 days, changing 
the water periodically. The polymers were filtered through PES syringe filters and freeze-
dried to yield all the respective quaternary ammonium polymers 5. NMR indicated 
conversion into the desired quaternary ammonium salts. 
 
Figure 6.6. Molecular structures of P5 polymer derivatives used for FRET NP studies. 
 
6.5.4 FRET NP Formation 
FRET NPs were generated using the P5 polymer scaffold, labelled either with 
donor Rhodamine Green or acceptor TRITC (Functionalized by incorporating a boc-
protected amino monomer during the polymerization, followed by purification using a 
10,000 MWCO dialysis bag). Keeping P5-Rhodamine Green’s concentration constant at 
~ 1.6µM in 2ml Eppendorf tubes, increasing concentrations of P5-TRITC in MQ water 
was added and the tubes were sonicated for one minute and allowed to stand for one hour. 
The solutions were then transferred to a 96-well microplate and the total emission spectrum 
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of both P5 derivatives were recorded on a SpectroMax M5 microplate reader (Molecular 
Device) using 480nm as the excitation wavelength (480nm was selected so that only P5-
Rhodamine Green would be excited). 
 
6.5.5 TEM Characterization of Polymeric Nanoparticles (NPs) 
TEM samples of polymers were prepared by placing one drop of the desired 
solution (10 μM) on to a 300-mesh Cu grid-coated with carbon film. These samples were 
analyzed and photographed using JEOL CX-100 electron microscopy. The average 
diameter of P5 nanoparticles is 12.7 ± 2.7 nm. 
 
Figure 6.7. TEM image of polymer nanoparticles. 
 
6.5.6 Biofilm Penetration Studies Using Confocal Laser Scanning Microscopy 
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108 bacterial cells/ml of DS Red (Red Fluorescent Protein) expressing E. coli, 
supplemented with 1mM of IPTG ((isopropyl β-D-1-thiogalactopyranoside), were seeded 
(2 ml in M9 media) in a confocal dish and were allowed to grow. After 3 days media was 
replaced by 1000 nM of PONI-C11-TMA-NPs and biofilms were incubated for 1 hour, 
biofilm samples incubated with only M9 media were used as control. After 1 h, biofilms 
were washed with PBS three times and were incubated with 100 μM of the substrates for 
1 h. The cells were then washed with PBS three times. Confocal microscopy images were 
obtained on a Zeiss LSM 510 Meta microscope by using a 63× objective. The settings of 
the confocal microscope were as follows: green channel: λex=488 nm and λem=BP 505-530 
nm; red channel: λex=543 nm and λem=LP 650 nm. Emission filters: BP=band pass, 
LP=high pass.  
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Figure 6.8. Penetration of Rhodamine Green labelled PONI-C11-TMA nanoparticles into 
DsRed expressing E. coli biofilms. The mean fluorescence of each confocal z-stack image 
was calculated using ImageJ software. 
 
6.5.7 Mammalian Cell Viability Assay57 
A total of 20,000 NIH 3T3 (ATCC CRL-1658) cells were cultured in Dulbecco's 
modified Eagle medium (DMEM; ATCC 30-2002) with 10% bovine calf serum and 1% 
antibiotics at 37 ºC in a humidified atmosphere of 5% CO2 for 48 h. Old media was 
removed and cells were washed one time with phosphate-buffered saline (PBS) before 
addition of NPs in the prewarmed 10% serum containing media. Cells were incubated for 
24 h at 37 ºC under a humidified atmosphere of 5% CO2. Cell viability was determined 
using Alamar blue assay according to the manufacturer's protocol (Invitrogen Biosource). 
After a wash step with PBS three times, cells were treated with 220 μL of 10% alamar blue 
in serum containing media and incubated at 37 ºC under a humidified atmosphere of 5% 
CO2 for 3 h. After incubation, 200 μL of solution from each well was transferred in a 96-
well black microplate. Red fluorescence, resulting from the reduction of Alamar blue 
solution, was quantified (excitation/emission: 560 nm/590 nm) on a SpectroMax M5 
microplate reader (Molecular Device) to determine the cellular viability. Cells without any 
NPs were considered as 100% viable. Each experiment was performed in triplicate. 
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Figure 6.9. Cytotoxicity of PNPs against NIH-3T3 Fibroblast cells. 
 
6.5.8 Therapeutic Indices Against Biofilms58 
Bacteria were inoculated in lysogeny broth (LB) medium at 37 ˚C until stationary 
phase. The cultures were then harvested by centrifugation and washed with 0.85% sodium 
chloride solution three times. Concentrations of resuspended bacterial solution were 
determined by optical density measured at 600 nm. Seeding solutions were then made in 
M9 medium to reach an OD600 of 0.1. A 100 μL amount of the seeding solutions was added 
to each well of the 96-well microplate. The plates were covered and incubated at room 
temperature under static conditions for 1 day. The stock solution of PONI-C11-TMA-NPs 
was then diluted to the desired level and incubated with the biofilms for 3 hours at 37˚C. 
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Biofilms were washed with phosphate buffer saline (PBS) three times and viability was 
determined using an Alamar Blue assay. Minimal M9 medium without bacteria was used 
as a negative control. Concentrations were converted to Log, plotted with bacteria viability, 
and fitted to a curve to determine the minimum biofilm eradication concentration at 90% 
(MBEC90).59 The therapeutic index with respect to red blood cells was calculated by the 
concentration of PONI-C11-TMA at MBEC90 divided by the hemolysis at 50%. 
 
Figure 6.10. Therapeutic indices of PNPs against four bacterial biofilms. 
 
6.5.9 Critical Micelle Concentration Study 
157 
 
Critical Micelle Concentration of P5 NP was determined through dilution of Nile 
Red encapsulated NPs. Briefly, 16.0 mg of Polymer P5 and 2.0 mg of Nile Red was 
dissolved in 2 ml of dimethylsulfoxide in a 7ml scintillation vial. While under vigorous 
stirring, 3 ml of water was slowly added over the course of 1 hour and allowed to stir 
overnight. Afterwards, the vial was centrifuged, and the solution decanted to remove 
precipitated Nile Red that was not encapsulated. Followed by filtration through a PES 
syringe filter, the solution was transferred to a 3,500 MWCO dialysis bag and allowed to 
stir in 5L of water for two days, changing the water twice each day. Afterwards, the solution 
was filtered again through a PES syringe filter yielding Nile Red encapsulated P5 NPs. 
Nile Red’s fluorescence spectrum was monitored (Excitation = 550nm) as a function of 
decreasing polymer concentration. it was observed that at 2.5 µM, fluorescence decrease 
became non-linear. Further dilution was not possible due to limitations in the amount of 
Nile Red encapsulated. Therefore, the critical micelle concentration was determined to be 
~ 2.5 µM and is well within the range of previously reported diblock polymer carriers.  
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Figure 6.11. Critical micelle concentration of P5 NPs. 
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CHAPTER 7 
HYBRIDIZED NANO-ASSEMBLIES: A PARADOX IN 
BIOFILM PENETRATION 
“Opinions from The PhD Candidate” 
 
7.1. Antimicrobial Nanocomposites 
A wide range of carvacrol-containing polymeric nanocomposites have been 
presented in Chapters 2 through 5, each containing the ability to penetrate bacterial 
biofilms and eliminate enclosed pathogens. While each composite scaffold contains the 
highly antimicrobial phytochemical carvacrol, the scaffold’s composite morphology 
throughout the oil phase and at the oil-water interface is largely different. Furthermore, 
the surface charge is vastly different between each composite. For instance, Chapter 2’s 
composite is crosslinked between a polymeric amine and polymeric anhydride, 
generating a large negative charge at the oil-water interface. Meanwhile Chapter 4’s 
composite is crosslinked between a polymeric maleimide and small-molecule disulfide-
dithiols, retaining an overall positive charge at the interface and would empirically adopt 
a largely different composite morphology throughout the nano-assembly. Given the 
notion in literature that cationic charge is critical for bacterial membrane binding and 
subsequent antimicrobial activity, why is that a highly negative charged composite can 
additionally penetrate and contribute nearly equal antimicrobial potency as compared to 
its cationic counterparts? To the best of my knowledge, other than literature publications 
highlighted in this thesis, there are no other literature examples discussing crosslinked 
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polymeric nanocomposites with antimicrobial phytochemicals. Therefore, future studies 
on these nano-assemblies will be fundamental to not only understand their physical and 
biochemical mechanisms, but to also further engineer improved nano-assemblies to fight 
against the dangers of MDR infections. The following are research considerations that 
should be investigated to further ascertain these undefined mechanisms and are merely 
opinions of this PhD candidate. 
7.1.1 Electrostatic Argument Doesn’t Hold with Biofilms 
While it is true that pathogens in their planktonic state will preferentially bind to 
cationic materials and subsequently lead to their demise, this argument does not hold 
ground when pathogens are colonized into complex 3-dimensional architectures such as 
biofilms. This argument holds even less merit when compounds containing true 
molecularity are constructed further into nanoarchitecture scaffolds or assemblies that have 
undefined morphologies due to characterization technique limitations. Previous reports 
have indicated that reactive oxidants and cationic molecules have slower penetration rates 
in biofilms and retard the materials through reaction, sorption, and diffusion processes. For 
instance, research performed by Li et al. showed that quantum dots bearing cationic charge 
ligands show little penetration, however adding localized hydrophobicity beyond the 
charged head group improved biofilm penetration.1 Although in this instance, negatively 
charge quantum dots did not penetrate, it is plausible the reason for this is derived from the 
quantum dots poor stability in a biofilm interface where a variety of biomass containing 
coordinating units like amines or thiols may result in ligand dissociation and nanomaterial 
aggregation, although the authors (myself included) showed no reports of this and was out 
of the scope of the study. A more defined example has been observed with liposomes. 
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Previous work has demonstrated that cationic liposomes could kill biofilm pathogens at a 
lower concentration than neutral or anionic counterparts, however anionic liposomes 
penetrated just as efficiently as their cationic counterparts. This result supports the notion 
described in Chapter 1 that penetration does not equal activity in addition to my suggestion 
that charge on complex nano-assemblies is a less critical parameter when determining 
activity, as demonstrated in Chapters 2 and 5. I will extend an olive branch however that if 
the antimicrobial component has inherent electrostatic attachments, then indeed charge 
matters. However, in the case of these phytochemical nano-assemblies, the antimicrobial 
component is largely hydrophobic and contains no bias charge. Therefore, I argue that 
electrostatics will never give us an answer into these phytochemical nano-assemblies 
mechanism(s) of action. I believe efforts into understanding mechanical changes to the 
biofilms EPS matrix upon interacting with phytochemical nano-assemblies will provide 
better insights to improve these antimicrobial designs.  
7.1.2 Consider Mechanical Dynamics 
The EPS matrix is responsible for nearly 90% of all the dry biomass within 
biofilms.2 Therefore, it is reasonable to suggest that EPS is fundamental for bacteria to 
survive in their static biofilm state by essentially being their life-line for nutrition, 
protection, and ultimately their release into the environment for further colonization.3 In 
many biofilm cases of P. aeruginosa the EPS is largely made of polysaccharides, Pel and 
Psl.4 Psl is fundamental for biofilms heterogenous, yet semi-ordered structure frame for the 
EPS matrix. Furthermore, Pel is surprisingly a cationic polysaccharide that crosslinks with 
eDNA additionally critical for biofilm morphology.  
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Each phytochemical nano-assembly had been subjected to biofilm penetration 
experiments using confocal microscopy. In every case, not only are the assemblies co-
localized with bacteria, but can also be found throughout the entire biofilm matrix. 
Therefore, I became very curious to observe what happens when phytochemical nano-
assemblies are added to extremely mature biofilms on a large Petri dish surface (Grown to 
a film thickness of a few millimeters). Within 10 seconds of incubation and very little 
agitation with my hand, I immediately noticed the biofilm became significantly less viscous 
and in fact the biofilm was completely removed from the plastic petri dish it was originally 
attached to. Therefore, I have reason to believe that the overall structural dynamic 
framework of EPS becomes severely compromised in the presence of these phytochemical 
nano-assemblies. I believe this hypothesis can be determined by generating Förster 
resonance energy transfer (FRET) labeled Pel and Psl polysaccharides and monitor the 
FRET signal prior to and after assembly incubation. Additionally, if Pel and Psl films could 
be generated on a surface and if these surfaces were incubated for a defined period, contact 
angle experiments may indicate differences in surface wettability prior to and after 
phytochemical nano-assembly incubation. Success of these experiments would garner 
support for my hypothesis and indicate mechanically compromised EPS is fundamental for 
antimicrobial activity of these assemblies enabling them to further penetrate and reach 
enclosed pathogens where the main antimicrobial component carvacrol can induce 
membrane disruption. However, I believe carvacrol does much more than disrupt pathogen 
membranes and can play an even greater role as a biochemical-mediated mechanical 
dynamic disruptor of the EPS matrix via Quorum Sensing Inhibition (QSI).5 
7.1.3 Consider Biochemical-Mediated Mechanical Dynamics 
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In addition to mechanical dynamics, Quorum Sensing (QS) can be considered a 
biochemical-mediated mechanical dynamic with biofilms. QS ultimately leads to biofilm 
growth and enzyme production necessary to provide biofilm homeostasis in the form of 
EPS breakdown or build-up through enzymes like chitinases, collagenases, elastases.6 
Therefore, inhibition of QS, QSI, would have dramatic effects not only on initial biofilm 
growth, but severely impair biofilm integrity, making it more susceptible to antimicrobial 
intervention. For instance, carvacrol has been known for some time to directly act as a QSI 
agent.7 Although the direct impact carvacrol has on biofilm growth is not well understood, 
there are literature precedence indicating its inhibition effects on Expl, a homoserine 
lactone synthase enzyme and ExpR, its respective regulatory protein.8 Furthermore, 
carvacrol has been demonstrated to inhibit certain enzymes critical in extracellular matrix 
decomposition such as chitinases, collagenases, and elastases. However, it should be noted 
that carvacrol works more effectively as a biofilm inhibitor and in some cases demonstrate 
no effect on pre-formed biofilms.9 I personally find this, scientifically-speaking, a huge 
opportunity to reinvestigate carvacrols activity now that carrier vehicles have been 
developed to enable complete phytochemical penetration into a biofilm matrix. If the 
scientific community were to explore QSI in the context of biofilm-penetrating nano-
assemblies, I believe additional insights into carvacrol’s or any other QSI agents activity 
on QS will become more apparent. Therefore, I suggest a repeat of prior experiments 
involving QSI agents loaded within these nano-assemblies. It may be possible to extract 
Pel/Psl from biofilms and appropriately label the polysaccharides with a carefully selected 
fluorophore that could be used as feed stock during biofilm growth. After these biofilms 
are grown with incorporated Pel/Psl feed-stock, morphological discrepancies could be 
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observed through confocal microscopy before and after the incubation of the 
phytochemical nano-assembly. Of course, careful selection of controls will be necessary, 
such as the use of a well known non-antimicrobial oil that previously showed no QSI 
activity. Although with that said, it is possible that prior non-active QSI agents may show 
activity upon encapsulation. If observed, this will open the possibility of discovering new 
QSI agents.  
7.2. Antimicrobial Polymeric Nanoparticles 
Chapter 6 discusses a synthetic engineering strategy to produce polymeric 
nanoparticles containing highly potent antimicrobial activities, even penetrating biofilms 
and eliminating enclosed pathogens. Prior to this research, literature insight over the past 
couple of decades has made it clear that careful consideration to the balance of 
hydrophobicity and cationic charge, or “Amphiphilic Balance”, must be made to ensure 
some level of antimicrobial selectivity to bacteria over mammalian cells.10 However, I was 
and still am not convinced “Amphiphilic Balance” is the only key parameter for 
antimicrobial selectivity towards bacteria. 
7.2.1 Looking Beyond Amphiphilic Balance and Membrane Disruption 
Work published by Sambhy et al. back in 2008, suggests that further consideration 
to the placement of local hydrophobic domains is equally critical, where it was observed 
that co-localization of the charge and hydrophobic domains reduces the antibacterial effect, 
however dramatically reduces the chance of red blood cell hemolysis.11 Without question, 
there needs to be more attention in the scientific community towards reducing hemolysis 
effects of their natural, synthetic, and engineered antimicrobial polymers. Inspired by this 
discovery, I wanted to monitor this effect using semi-rigid Poly(Oxanorbornene) polymers 
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and instead of having the hydrophobic domain exterior to the charge head group, we 
embedded the domain as a bridge between the polymer backbone and charged head group. 
My reasoning for this selection was partially based on a previous work reported by Li et 
al. where they observed that increasing the hydrophobic domain exterior to the charge 
group increased the chance for red blood cell hemolysis and in fact, we see this same effect 
on these polymer scaffolds.12 Combined with the notion that mammalian cell membranes 
are vastly more zwitterionic than their bacteria counterparts (negatively charged), we 
hypothesize these polymers are not capable of interacting with mammalian membranes as 
the hydrophobic domains are buried within the scaffold. Furthermore, we believe that once 
these polymers interact with bacterial membranes, their polymeric particle structure 
“unfolds” allowing the polymers to imbed, compromising membrane integrity, leading to 
its antimicrobial activity. Therefore, future work could reside in determining this proposed 
mechanism using a fluorescence recovery after photobleaching (FRAP) experiment, 
described in the following work which successfully applied this technique to the 
mammalian antimicrobial peptide LL-37.13 
While the following proposed experiment can be used to monitor these polymeric 
nanoparticles effect on bacterial membranes, I am reluctant to believe that membrane 
disruption is the only activity these polymers have. Even though propidium iodide 
experiments indicate bacteria undergo membrane disruption, the disruption may arise from 
the polymers binding to extracellular DNA. This can result in DNA aggregation or 
inhibition of protein transcription that ultimately leads to a compromised membrane. Work 
published recently by Gupta et al. identified that the activity of their antimicrobial gold 
nanoparticles goes beyond membrane disruption and through proteomic analysis, indicated 
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a significant down-regulation of efflux pump membrane proteins.14 I believe a similar study 
should be applied to these polymeric nanoparticle systems to better ascertain less obvious 
action mechanisms that can attribute to the observed membrane disruption experiments. 
7.2.2 Further Analysis into Polymeric Nanoparticle-Biofilm Dynamics 
Furthermore, understanding how these polymeric nanoparticles can penetrate 
biofilms and eliminating enclosed pathogens is an equally important next step. Previous 
studies on antimicrobial peptides indicate they are capable of penetrating biofilms, 
however are less effective against mature biofilms.15 This empirically makes sense as any 
oligomeric or polymeric cationic material posses strong binding affinities to respective 
anionic materials enclosed within the biofilm matrix such as eDNA. In fact, previous 
studies have indicated that mature biofilms incubated with antimicrobial peptides are 
unable to reach enclosed pathogens and become either sequestered via electrostatic 
interactions with eDNA.16 Alternatively, cationic polymeric materials within the biofilm 
matrix prevent penetration through electrostatic repulsion. I believe the polymeric 
nanoparticles presented in Chapter 6 falls victim to the same outcome and evidence of this 
observation can be seen in the confocal microscopy experiments monitoring penetration 
depth. While fluorescence signatures from the polymer is shown co-localized with bacteria, 
polymers can be seen adhered throughout the film, most likely binding to anionic 
biomaterials enclosed within the matrix. I hypothesize that quantitative proof of this 
interaction can be performed in a similar fashion as proposed in the antimicrobial 
nanocomposite section. If eDNA can be isolated, carefully labelled with a FRET dye, and 
reintroduced back as a feed stock for biofilm growth, a respective FRET dye can be added 
within the polymeric nanoparticle and monitor any observed FRET signatures. Success of 
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this experiment would heavily support the notion of polymeric entanglement with the 
biofilm matrix as it was observed the amount of polymer necessary to kill biofilms 
increases from low nanomolar to low micromolar concentrations. 
7.2.3 Optimization to Prevent Protein Fouling 
While the polymer nanoparticles presented in Chapter 6 demonstrate low MICs, 
great hemolytic activities, and biofilm penetration, these valuable characteristics nearly 
disappear in vitro when incubated in a media that contains negatively charged serum 
proteins. Preliminary dynamic light scattering (DLS) experiments indicate that when these 
polymer nanoparticles are in the presence of serum proteins, a single protein will adhere, 
changing the nanomaterials composition and overall charge. This is not surprising as 
numerous nanomaterials fail in vivo due to protein corona formation.17 Therefore, 
additional optimization of the polymeric nanoparticles will need to be performed, followed 
by testing their MICs with planktonic bacteria in non-serum and serum containing media. 
One plausible strategy that demonstrated success in Chapter 2 is to generate polymeric 
nanoparticles that bear an overall negative charge. This would, in theory, reduce protein 
corona formation due to electrostatic repulsion. Careful selection into what anionic group 
to use will be critical as to not compromise membrane adhesion onto bacterium. I 
hypothesize that given the nature of these polymeric nanoparticles, initial adherence may 
result in morphological changes of the particles, allowing them to embed within the 
membranes resulting in a killing effect. However, reinvestigation into bacterium 
proteomics will need to be performed as an anionic polymeric nanoparticle may show 
discrepancies in its activity compared to its cationic analogs. If successful, I am confident 
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anionic analogs will be capable of penetrating biofilms, although penetration kinetics will 
change accordingly. 
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